{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-11T18:22:35.383154Z",
     "start_time": "2019-03-11T18:22:33.152126Z"
    }
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Populating the interactive namespace from numpy and matplotlib\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "%pylab inline"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Drugs table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-07T17:49:35.499115Z",
     "start_time": "2019-03-07T17:49:34.630517Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(1203, 36)"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "drugs = pd.read_excel('bcdrugs.xlsx')\n",
    "drugs.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Drugs columns = 'Drug ID', 'Drug Name', 'CAS Number', 'Chemical Name',\n",
    "       'New Molecular Entity', 'Drug Interactions', 'Comparative Efficacy',\n",
    "       'Highest Development Phase', 'Indication', 'Molecular Formula',\n",
    "       'Mechanism Of Action', 'Organisation',\n",
    "       'Pharmacodynamic Characteristics', 'Route Of Administration',\n",
    "       'Route Of Elimination', 'Pharmacokinetic Characteristics',\n",
    "       'Adverse Events', 'Therapeutic Class (EphMRA)',\n",
    "       'Therapeutic Class (WHO)', 'Synonyms/Brand Names',\n",
    "       'Antimicrobial Activity', 'Immunogenicity',\n",
    "       'Last Significant Update Date', 'Therapeutic Area',\n",
    "       'Orphan Designation', 'License Availability', 'Brands', 'On Fastrack',\n",
    "       'Fastrack country', 'On PRIME', 'PRIME country', 'Biomarkers-Inclusion',\n",
    "       'Biomarkers-Exclusion', 'Biomarkers-Outcome Measure',\n",
    "       'Biomarkers-Safety', 'Biomarkers-not specified'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-07T20:00:02.165295Z",
     "start_time": "2019-03-07T20:00:02.141577Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Marketed                                     175\n",
       "Preclinical                                  167\n",
       "Phase II                                     149\n",
       "No development reported (Preclinical)         87\n",
       "Phase III                                     84\n",
       "Discontinued (II)                             84\n",
       "Phase I                                       65\n",
       "Discontinued (Preclinical)                    60\n",
       "Discontinued (III)                            46\n",
       "Phase I/II                                    44\n",
       "Research                                      35\n",
       "Discontinued (I)                              25\n",
       "No development reported (Research)            21\n",
       "No development reported (I)                   21\n",
       "No development reported (II)                  20\n",
       "Registered                                    15\n",
       "Phase II/III                                  14\n",
       "Discontinued (I/II)                           11\n",
       "Discontinued (Preregistration)                10\n",
       "No development reported (Clinical)            10\n",
       "Preregistration                               10\n",
       "Clinical Phase Unknown                         7\n",
       "No development reported (I/II)                 7\n",
       "Suspended (I)                                  5\n",
       "Suspended (II)                                 5\n",
       "Discontinued (Clinical)                        4\n",
       "Suspended (III)                                3\n",
       "No development reported (III)                  3\n",
       "No development reported                        2\n",
       "No development reported (Preregistration)      2\n",
       "Discontinued (Registered)                      2\n",
       "Discontinued (II/III)                          2\n",
       "Phase Unknown                                  2\n",
       "Market Withdrawal                              1\n",
       "Discontinued                                   1\n",
       "No development reported (Registered)           1\n",
       "Preregistration Submission Withdrawal          1\n",
       "Discontinued (Research)                        1\n",
       "Phase 0                                        1\n",
       "Name: Highest Development Phase, dtype: int64"
      ]
     },
     "execution_count": 81,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "drugs['Highest Development Phase'].value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Trials table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-11T18:22:40.900900Z",
     "start_time": "2019-03-11T18:22:36.968556Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(4529, 41)"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials = pd.read_excel('bcdrugsct.xlsx')\n",
    "trials.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 159,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-12T00:50:16.830609Z",
     "start_time": "2019-03-12T00:50:16.771118Z"
    }
   },
   "outputs": [],
   "source": [
    "cols = ['Trial ID','Mechanism of action', 'Drug class (therapeutic effect)', 'Drug class (chemical)', \\\n",
    "        'Indication', 'Organisations', 'Trial Design', 'Location', 'Phase of Trial', 'Subject Age',\\\n",
    "        'Planned Subject Number', 'Trial Centre Details', 'Lead Centre', 'Trial Initiation date', \\\n",
    "        'Trial End date', 'Trial Status', 'Trial History', 'Diseases treated', 'Primary Drugs']\n",
    "smaller_trials = trials[cols]\n",
    "date_cols = ['Phase of Trial','Trial Initiation date', 'Trial End date', 'trial_start','trial_end']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 133,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-12T00:27:55.386344Z",
     "start_time": "2019-03-12T00:27:55.367923Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1      01 Dec 2013 (actual)\n",
       "10     01 Dec 2015 (actual)\n",
       "16     12 Feb 2019 (actual)\n",
       "478    06 Dec 2018 (actual)\n",
       "481    01 Feb 2014 (actual)\n",
       "Name: Trial Initiation date, dtype: object"
      ]
     },
     "execution_count": 133,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['Trial Initiation date'].head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-12T01:15:01.675640Z",
     "start_time": "2019-03-12T01:15:01.556606Z"
    }
   },
   "outputs": [],
   "source": [
    "\n",
    "def phase_1(drug_name):\n",
    "    '''\n",
    "    take earliest Phase I date and latest Phase II\n",
    "    '''\n",
    "    tucatinib_trials = trials[trials['Primary Drugs']==drug_name]\n",
    "    trial_phases = ['Phase I', 'Phase II', 'Phase III']\n",
    "    cleaned_tucatinib_trials = tucatinib_trials[tucatinib_trials['Phase of Trial'].isin(trial_phases)]\n",
    "    phase_dummies = pd.get_dummies(cleaned_tucatinib_trials['Phase of Trial'])\n",
    "    cleaned_tucatinib_trials_dummies = cleaned_tucatinib_trials.join(phase_dummies)\n",
    "    #cleaned_tucatinib_trials_dummies[['Trial Initiation date', 'Trial End date']]\n",
    "    df = cleaned_tucatinib_trials.join(phase_dummies)\n",
    "\n",
    "    #not DRY as the answers to make multiargument apply functions involved more complicated things than I wanted.\n",
    "    def start_to_datetime(x):\n",
    "        date_str = re.findall('[\\d\\s\\w]*', x['Trial Initiation date'])[0].strip()\n",
    "        if date_str == '':\n",
    "            return False\n",
    "        else:\n",
    "            return pd.to_datetime(date_str)\n",
    "\n",
    "    def end_to_datetime(x):\n",
    "        date_str = re.findall('[\\d\\s\\w]*', x['Trial End date'])[0].strip()\n",
    "        if date_str == '':\n",
    "            return False\n",
    "        else:\n",
    "            return pd.to_datetime(date_str)\n",
    "\n",
    "    df['trial_start'] = df.apply(start_to_datetime, axis=1)\n",
    "    df['trial_end'] = df.apply(end_to_datetime, axis=1)\n",
    "\n",
    "    t_phase_1_min = min(list(df[(df['trial_start']!=False) & (df['Phase of Trial']=='Phase I')]['trial_start'].values))\n",
    "    t_phase_1_max = max(list(df[(df['trial_start']!=False) & (df['Phase of Trial']=='Phase I')]['trial_start'].values))\n",
    "\n",
    "    return f'min is {t_phase_1_min} and max is {t_phase_1_max}'\n",
    "\n",
    "phase_1('Xentuzumab')\n",
    "\n",
    "\n",
    "# df['split_start_date'] = df['Trial Initiation date'].apply(lambda x: x.split(' '))\n",
    "# df['split_end_date'] = df['Trial End date'].apply(lambda x: x.split(' '))\n",
    "# df2 = df[df['split_start_date'].apply(lambda x: len(x[:3]))==3]\n",
    "# df3 = df2[df2['split_end_date'].apply(lambda x: len(x[:3]))==3]\n",
    "# df3[date_cols]\n",
    "#df3.apply(lambda x: ' '.join(x['split_start_date']))\n",
    "# in_progress_trials = trials[trials['split_start_date'].apply(lambda x: len(x[:3]))==3]\n",
    "# planned_trials = trials[trials['split_start_date'].apply(lambda x: len(x[:3]))==2]\n",
    "# # one_split = trials['split_end_date'].values[0]\n",
    "# # pd.to_datetime(' '.join(one_split[:3]))\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-11T23:24:38.481578Z",
     "start_time": "2019-03-11T23:24:38.448205Z"
    }
   },
   "outputs": [],
   "source": [
    "phase_two = smaller_trials[smaller_trials['Phase of Trial'] == 'Phase II']\n",
    "phase_three = smaller_trials[smaller_trials['Phase of Trial'] == 'Phase III']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-11T23:28:49.038299Z",
     "start_time": "2019-03-11T23:28:49.023698Z"
    }
   },
   "outputs": [],
   "source": [
    "unique_drugs =list(smaller_trials['Primary Drugs'].unique())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 185,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-12T01:14:30.714538Z",
     "start_time": "2019-03-12T01:14:30.688232Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['AB-928',\n",
       " 'Tucatinib',\n",
       " 'Lenvatinib, Pembrolizumab',\n",
       " 'Bevacizumab, Paclitaxel',\n",
       " 'Xentuzumab',\n",
       " 'Pembrolizumab',\n",
       " 'Taselisib',\n",
       " 'Adavosertib, Afatinib, AZD 4547, Binimetinib, Capivasertib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, GSK 2636771, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Trastuzumab emtansine, Vismodegib',\n",
       " 'Anastrozole, Exemestane, Fulvestrant, Letrozole, Palbociclib',\n",
       " 'Trastuzumab emtansine',\n",
       " 'Pertuzumab',\n",
       " 'KN 035',\n",
       " 'Gallium 68 satoreotide, Lutetium-177-DOTA-satoreotide',\n",
       " 'Avelumab, TRX 518',\n",
       " 'Varlitinib',\n",
       " 'Capecitabine, Tesetaxel',\n",
       " 'Fulvestrant',\n",
       " 'Afatinib',\n",
       " 'Celecoxib',\n",
       " 'Nivolumab, Trastuzumab-deruxtecan',\n",
       " 'Abiraterone acetate',\n",
       " 'Exemestane',\n",
       " 'AZD 4547',\n",
       " 'Margetuximab',\n",
       " 'Capivasertib',\n",
       " 'Alpelisib, Fulvestrant, Letrozole',\n",
       " 'Eribulin',\n",
       " 'Bevacizumab',\n",
       " 'Cyclophosphamide, Pertuzumab, Trastuzumab',\n",
       " 'Autologous cytotoxic T cell therapeutic Marker Cell Therapeutics',\n",
       " 'Tetrathiomolybdate',\n",
       " 'Trastuzumab',\n",
       " 'Debio 1347',\n",
       " 'Pertuzumab, Pertuzumab/trastuzumab, Trastuzumab',\n",
       " 'Onalespib, Paclitaxel',\n",
       " 'Everolimus',\n",
       " 'Durvalumab, Olaparib',\n",
       " 'ARQ 751',\n",
       " 'Abemaciclib',\n",
       " 'Mifepristone',\n",
       " 'Nelipepimut-S',\n",
       " 'Exemestane, Tamoxifen',\n",
       " 'Endoxifen',\n",
       " 'Avelumab, Talazoparib',\n",
       " 'Enzastaurin',\n",
       " 'Veliparib',\n",
       " 'Erdafitinib',\n",
       " 'Carboplatin, LAG 525, Spartalizumab',\n",
       " 'Entinostat',\n",
       " 'SAR-439859',\n",
       " 'Capecitabine, Everolimus',\n",
       " 'Palbociclib, Trastuzumab emtansine',\n",
       " 'Trastuzumab-duocarmazine-Synthon-Biopharmaceuticals',\n",
       " 'RO 6874281',\n",
       " 'FLX-475',\n",
       " 'Olaparib',\n",
       " 'Letrozole, Palbociclib',\n",
       " 'Indoximod',\n",
       " 'Talazoparib',\n",
       " 'Vinorelbine',\n",
       " 'Alpelisib, Fulvestrant',\n",
       " nan,\n",
       " 'Ipilimumab, Nivolumab',\n",
       " 'Rucaparib',\n",
       " 'Enobosarm',\n",
       " 'ONC 201',\n",
       " 'Carotuximab',\n",
       " 'Larotrectinib',\n",
       " 'Pembrolizumab, PGG-glucan',\n",
       " 'Palbociclib',\n",
       " 'Sacituzumab govitecan',\n",
       " 'Eribulin, Hyaluronidase',\n",
       " 'Trastuzumab-deruxtecan',\n",
       " 'Ribociclib',\n",
       " 'Cirmtuzumab, Paclitaxel',\n",
       " 'AZD 9833',\n",
       " 'Poly(ADP-ribose) polymerase inhibitors, Tazemetostat',\n",
       " 'Anlotinib, TQB-2450',\n",
       " 'Carboplatin, Ipatasertib, Paclitaxel',\n",
       " 'COM 701, Nivolumab',\n",
       " 'AVB 620',\n",
       " 'Ipatasertib, Paclitaxel',\n",
       " 'Bosutinib, Fulvestrant, Palbociclib',\n",
       " 'LYC 55716',\n",
       " 'SPARC-1613',\n",
       " 'Atezolizumab, Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab',\n",
       " 'G1T-48',\n",
       " 'Avelumab, PD 360324, PF 4518600, Utomilumab',\n",
       " 'Alpelisib',\n",
       " 'PF 06936308',\n",
       " 'Atezolizumab, Cabozantinib',\n",
       " 'Bempegaldesleukin, Nivolumab, NKTR-262',\n",
       " 'Denosumab',\n",
       " 'Trilaciclib',\n",
       " 'Atezolizumab',\n",
       " 'KN-026',\n",
       " 'SAR 566658',\n",
       " 'Lapatinib, Trastuzumab',\n",
       " 'CX 2009',\n",
       " 'Aromatase inhibitors, Fulvestrant, Sulforafan, Tamoxifen',\n",
       " 'Antineoplastics',\n",
       " 'Fulvestrant, Gedatolisib, Letrozole, Palbociclib',\n",
       " 'Ixabepilone, Paclitaxel',\n",
       " 'Hu5F9 G4',\n",
       " 'Lapatinib',\n",
       " 'CX 072, Ipilimumab, Vemurafenib',\n",
       " 'Lerociclib',\n",
       " 'Copanlisib, Metformin',\n",
       " 'Carboplatin, Docetaxel, Pyrotinib, Trastuzumab',\n",
       " 'Anastrozole',\n",
       " 'Nivolumab, Pembrolizumab, Vopratelimab',\n",
       " 'Olaparib, Onalespib',\n",
       " 'Pembrolizumab, Talimogene laherparepvec',\n",
       " 'Fulvestrant, Palbociclib',\n",
       " 'Ruxolitinib',\n",
       " 'Rucaparib, Sacituzumab govitecan',\n",
       " 'Carboplatin, Paclitaxel, Talazoparib',\n",
       " 'Gedatolisib',\n",
       " 'FPA 150',\n",
       " 'Galunisertib',\n",
       " 'Bicalutamide, Ribociclib',\n",
       " 'Abemaciclib, Trastuzumab, Tucatinib',\n",
       " 'CB 103',\n",
       " 'Abemaciclib, Fulvestrant',\n",
       " 'Durvalumab, Tremelimumab',\n",
       " 'Paclitaxel',\n",
       " 'Pembrolizumab, XmAb-22841',\n",
       " 'Capecitabine',\n",
       " 'Doxorubicin liposomal',\n",
       " 'XmAb-20717',\n",
       " 'Celecoxib, Interferon alpha-2b, Pembrolizumab, Rintatolimod',\n",
       " 'Everolimus, Exemestane, Xentuzumab',\n",
       " 'Gemcitabine',\n",
       " 'XmAb-23104',\n",
       " 'Pertuzumab, Trastuzumab',\n",
       " 'Alisertib',\n",
       " 'Carboplatin, Gemcitabine, Paclitaxel',\n",
       " 'Atezolizumab, Emactuzumab',\n",
       " 'Atezolizumab, Rucaparib',\n",
       " 'Exemestane, Fulvestrant, Palbociclib',\n",
       " 'Canakinumab, Capmatinib, Lacnotuzumab, LAG 525, NIR 178, Spartalizumab',\n",
       " 'Alpelisib, Ribociclib',\n",
       " 'Anastrozole, Fulvestrant',\n",
       " 'Paclitaxel, Pembrolizumab, Pertuzumab, Trastuzumab',\n",
       " 'BI 754091',\n",
       " 'Anastrozole, Goserelin, Letrozole, Ribociclib',\n",
       " 'Ipatasertib, Rucaparib',\n",
       " 'Docetaxel',\n",
       " 'Atezolizumab, Pertuzumab, Trastuzumab',\n",
       " 'MBS 301',\n",
       " 'Bevacizumab, Gemcitabine',\n",
       " 'Conjugated estrogens/bazedoxifene',\n",
       " 'NIR 178, Spartalizumab, SRF-373',\n",
       " 'Denosumab, Pamidronic acid, Zoledronic acid',\n",
       " 'M 6620',\n",
       " 'Entrectinib',\n",
       " 'Gallium 68 NeoBOMB1',\n",
       " 'Tesetaxel',\n",
       " 'Interferon alpha-2a, Pazopanib',\n",
       " 'ARQ 761',\n",
       " 'Durvalumab, Exemestane, Tremelimumab',\n",
       " 'Gallium 68 RM2',\n",
       " 'Cediranib, Olaparib',\n",
       " 'Tavokinogene telsaplasmid',\n",
       " 'PMD 026',\n",
       " 'Letrozole, Pyrotinib, SHR 6390',\n",
       " 'Olaparib, Trastuzumab',\n",
       " 'Infigratinib',\n",
       " 'Cisplatin, Pembrolizumab',\n",
       " 'PF-06952229',\n",
       " 'Lurbinectedin',\n",
       " 'Enzalutamide',\n",
       " 'Capecitabine, Eribulin',\n",
       " 'Andecaliximab',\n",
       " 'OTS 167',\n",
       " 'Atezolizumab, Olaparib',\n",
       " 'Adavosertib, AZD 6738, Olaparib',\n",
       " 'GDC-0077',\n",
       " 'BAY 869596',\n",
       " 'Crenigacestat',\n",
       " 'FAZ 053, Spartalizumab',\n",
       " 'BAY 949392',\n",
       " 'Mivebresib, Venetoclax',\n",
       " 'Leronlimab',\n",
       " 'Etirinotecan pegol',\n",
       " 'Letrozole',\n",
       " 'Neratinib',\n",
       " 'SV-BR-1-GM breast cancer vaccine BriaCell Therapeutics',\n",
       " 'Sorafenib',\n",
       " 'Estetrol',\n",
       " 'Fulvestrant, Pembrolizumab',\n",
       " 'Bevacizumab, Letrozole, Tamoxifen',\n",
       " 'CX 5461',\n",
       " 'Atezolizumab, Paclitaxel',\n",
       " 'Venetoclax',\n",
       " 'Durvalumab',\n",
       " 'AZD 9496',\n",
       " 'Rituximab, Utomilumab',\n",
       " 'Nidanilimab',\n",
       " 'ABBV-155',\n",
       " 'Paclitaxel, Telaglenastat',\n",
       " 'Nivolumab',\n",
       " 'Vistusertib',\n",
       " 'GDC 0084, Trastuzumab',\n",
       " 'Atezolizumab, Bevacizumab, Cobimetinib, Exemestane, Ipatasertib, Tamoxifen',\n",
       " 'Letrozole, Ribociclib',\n",
       " 'Palbociclib, ZN c5',\n",
       " 'Telaglenastat',\n",
       " 'Atezolizumab, Navoximod',\n",
       " 'Atezolizumab, Cobimetinib, Eribulin',\n",
       " 'Vismodegib',\n",
       " 'Bempegaldesleukin, Ipilimumab, Nivolumab',\n",
       " 'Eribulin, Pembrolizumab',\n",
       " 'Fulvestrant, Letrozole, Palbociclib',\n",
       " 'Mammaglobin A DNA vaccine',\n",
       " 'Poziotinib',\n",
       " 'Orlotamab',\n",
       " 'IC 2000',\n",
       " 'Adavosertib',\n",
       " 'Prexasertib',\n",
       " 'Erlotinib, Fulvestrant',\n",
       " 'EC 1456, Technetium Tc99m etarfolatide',\n",
       " 'ALKS 4230, Pembrolizumab',\n",
       " 'Capecitabine, Lapatinib',\n",
       " 'Anastrozole, Everolimus, Exemestane, Fulvestrant, Letrozole, Tamoxifen',\n",
       " 'Vinorelbine, Vinorelbine',\n",
       " 'Trastuzumab-conjugate',\n",
       " 'Eribulin, Trastuzumab',\n",
       " 'NED-170',\n",
       " 'Anastrozole, Palbociclib, Pertuzumab, Trastuzumab',\n",
       " 'ABBV 181',\n",
       " 'Capecitabine, Ribociclib',\n",
       " 'GDC-9545',\n",
       " 'Anastrozole, Aromatase inhibitors, Everolimus, Exemestane, Letrozole',\n",
       " 'Copanlisib, Fulvestrant',\n",
       " 'Ladiratuzumab-Vedotin, Pembrolizumab',\n",
       " 'Galinpepimut S, Pembrolizumab',\n",
       " 'ODM 209',\n",
       " 'Alpelisib, Everolimus',\n",
       " 'Irosustat',\n",
       " 'Trastuzumab, Trastuzumab',\n",
       " 'INXN 2001',\n",
       " 'Pertuzumab, Tocilizumab, Trastuzumab',\n",
       " 'Carboplatin, Cyclophosphamide, Denosumab, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab',\n",
       " 'Everolimus, Lapatinib',\n",
       " 'Avelumab, Fulvestrant, Palbociclib',\n",
       " 'Bexarotene',\n",
       " 'TAEST 16001',\n",
       " 'FATE NK100',\n",
       " 'Cixutumumab',\n",
       " 'Neratinib, Vinorelbine',\n",
       " 'Irinotecan, Veliparib',\n",
       " 'Gimeracil/oteracil/tegafur, Trastuzumab',\n",
       " 'Cyclophosphamide, Veliparib',\n",
       " 'Temsirolimus',\n",
       " 'Celecoxib, Trastuzumab',\n",
       " 'Brilanestrant',\n",
       " 'Durvalumab, Fulvestrant, Tremelimumab',\n",
       " 'Entinostat, Lapatinib, Trastuzumab',\n",
       " 'Buparlisib',\n",
       " 'Bimiralisib, Eribulin',\n",
       " 'Fulvestrant, Lapatinib',\n",
       " 'CDX 1140, FLT-3 ligand',\n",
       " 'Entinostat, Nivolumab',\n",
       " 'Pertuzumab, Trastuzumab emtansine',\n",
       " 'Elacestrant',\n",
       " 'MORAb-202',\n",
       " 'EDP-1503, Pembrolizumab',\n",
       " 'AMG 110',\n",
       " 'Seviteronel',\n",
       " 'PF-06804103',\n",
       " 'Tucidinostat',\n",
       " 'LY 3023414',\n",
       " 'Cisplatin',\n",
       " 'Glembatumumab vedotin',\n",
       " 'Pazopanib',\n",
       " 'Abemaciclib, Pembrolizumab',\n",
       " 'INGN 225',\n",
       " 'Bevacizumab, ME 344',\n",
       " 'Omega-3-acid ethyl esters',\n",
       " 'Alpelisib, Enzalutamide',\n",
       " 'Simvastatin',\n",
       " 'E-7130',\n",
       " 'Bevacizumab, Trastuzumab',\n",
       " 'ALRN 6924, Paclitaxel',\n",
       " 'ZW 49',\n",
       " 'Capecitabine, Vinorelbine',\n",
       " 'CPI 444, CPI-006, Pembrolizumab',\n",
       " 'ABBV 151, ABBV 181',\n",
       " 'Aromatase inhibitors, Fulvestrant, LHRH receptor agonists, Palbociclib, Selective estrogen receptor modulators, Tamoxifen',\n",
       " 'Alpelisib, Buparlisib',\n",
       " 'Epacadostat, Pembrolizumab',\n",
       " 'Rosuvastatin',\n",
       " 'Durvalumab, Pertuzumab, Trastuzumab',\n",
       " 'BOS 172722',\n",
       " 'Bemcentinib, Pembrolizumab',\n",
       " 'Ixabepilone',\n",
       " 'Rebastinib',\n",
       " 'Vorinostat',\n",
       " 'Nivolumab, ONO 4578',\n",
       " 'Ipilimumab, Pembrolizumab, SV-BR-1-GM breast cancer vaccine BriaCell Therapeutics',\n",
       " 'GS 5829',\n",
       " 'Letrozole, SHR 6390',\n",
       " 'Vandetanib',\n",
       " 'Proxalutamide',\n",
       " 'Pembrolizumab, Tavokinogene telsaplasmid',\n",
       " 'Toripalimab',\n",
       " 'Trastuzumab, Vinorelbine',\n",
       " 'Atezolizumab, RG 6146',\n",
       " 'NK 012',\n",
       " 'H3B-6545',\n",
       " 'Atezolizumab, Bevacizumab, Cobimetinib, Ipatasertib, Ladiratuzumab-Vedotin',\n",
       " 'Bevacizumab, Nivolumab, Paclitaxel',\n",
       " 'Tipifarnib',\n",
       " 'Pembrolizumab, Tanibirumab',\n",
       " 'U3 1402',\n",
       " 'Triciribine',\n",
       " 'PU H71',\n",
       " 'AVID 100',\n",
       " 'Capivasertib, Danvatirsen, Durvalumab, Oleclumab, Paclitaxel, Selumetinib',\n",
       " 'IPI 549, Nivolumab',\n",
       " 'Foxy 5',\n",
       " 'Nivolumab, TAK 659',\n",
       " 'Erdafitinib, Fulvestrant, Palbociclib',\n",
       " 'Oleclumab',\n",
       " 'Pertuzumab, Trastuzumab, Vinorelbine',\n",
       " 'LY 2780301, Paclitaxel',\n",
       " 'Pembrolizumab, Tamoxifen, Vorinostat',\n",
       " 'GLG 801',\n",
       " '4-hydroxytestosterone',\n",
       " 'Eribulin, Olaparib',\n",
       " 'BAY 1834942, Pembrolizumab',\n",
       " 'CAB-ROR2-ADC',\n",
       " 'D 0502',\n",
       " 'Capivasertib, Fulvestrant, Neratinib',\n",
       " 'RC 48',\n",
       " 'S 81694',\n",
       " 'Pegfilgrastim',\n",
       " 'LAG 525, Spartalizumab',\n",
       " 'Alpelisib, LSZ 102, Ribociclib',\n",
       " 'Cyclophosphamide, Pembrolizumab',\n",
       " 'ABT 767',\n",
       " 'DHES-0815A',\n",
       " 'Fulvestrant, Vistusertib',\n",
       " 'MEN 1611, Trastuzumab',\n",
       " 'Talimogene laherparepvec',\n",
       " 'Pertuzumab/trastuzumab',\n",
       " 'Alisertib, Sapanisertib',\n",
       " 'Goserelin, Letrozole, Palbociclib',\n",
       " 'Neratinib, Paclitaxel',\n",
       " 'Atezolizumab, Talimogene laherparepvec',\n",
       " 'Seribantumab',\n",
       " 'NIR 178, Spartalizumab',\n",
       " 'BTP 114',\n",
       " 'Adagloxad simolenin, OPT 821',\n",
       " 'Nivolumab, Paclitaxel',\n",
       " 'Atezolizumab, Bevacizumab',\n",
       " 'Cobimetinib, Ipilimumab, Nivolumab',\n",
       " 'Anastrozole, Letrozole, Ribociclib',\n",
       " 'MEN 1309',\n",
       " 'Capecitabine, Neratinib',\n",
       " 'Recombinant polio virus vaccine Istari Oncology',\n",
       " 'Letrozole, Nintedanib',\n",
       " 'A-166',\n",
       " 'Avelumab, Trastuzumab, Utomilumab, Vinorelbine',\n",
       " 'Everolimus, Exemestane',\n",
       " 'Atezolizumab, Cobimetinib, Paclitaxel',\n",
       " 'Daratumumab, Nivolumab',\n",
       " 'Atezolizumab, Ipatasertib, Paclitaxel',\n",
       " 'PF-06873600',\n",
       " 'Fulvestrant, Ribociclib',\n",
       " 'ASP-1948',\n",
       " 'Camrelizumab, Rivoceranib',\n",
       " 'Tc 99m sulfur colloid, Tc 99m tilmanocept',\n",
       " 'XMT 1522',\n",
       " 'LY 2880070',\n",
       " 'Granulocyte-macrophage colony-stimulating factors, TPIV 200',\n",
       " 'TPIV 100',\n",
       " 'Bintrafusp alfa',\n",
       " 'Seclidemstat',\n",
       " 'Docetaxel, MK 0752',\n",
       " 'Bisphosphonates, Denosumab',\n",
       " 'SY 1365',\n",
       " 'BP-C1',\n",
       " 'Ladiratuzumab-Vedotin',\n",
       " 'Ipatasertib',\n",
       " 'BTRC-4017A',\n",
       " 'Ixazomib',\n",
       " 'Aspirin, Avelumab, Lansoprazole',\n",
       " 'Gimeracil/oteracil/tegafur, Irinotecan, Trastuzumab',\n",
       " 'Abemaciclib, Xentuzumab',\n",
       " 'GSK-3145095, Pembrolizumab',\n",
       " 'Anti-mesothelin chimeric antigen receptor T cell therapy Atara Biotherapeutics',\n",
       " 'Dasatinib',\n",
       " 'Fimepinostat',\n",
       " 'Capecitabine, Trastuzumab, Tucatinib',\n",
       " 'Zoledronic acid',\n",
       " 'Eribulin, Pertuzumab, Trastuzumab',\n",
       " 'Interleukin-12',\n",
       " 'Nirogacestat',\n",
       " 'Niraparib, Trastuzumab',\n",
       " 'ACTR707, Trastuzumab',\n",
       " 'Docetaxel, Paclitaxel, Pertuzumab/trastuzumab',\n",
       " 'Temozolomide, Veliparib',\n",
       " 'Letrozole, Palbociclib, Pertuzumab, Trastuzumab',\n",
       " 'Everolimus, Exemestane, Ribociclib',\n",
       " 'Radium 223 chloride',\n",
       " 'ATL 101 Telix Pharmaceuticals',\n",
       " 'Ganetespib',\n",
       " 'Fulvestrant, Vandetanib',\n",
       " 'Sapacitabine, Seliciclib',\n",
       " 'AB-928, IPI 549',\n",
       " 'Nintedanib, Pembrolizumab',\n",
       " 'Erlotinib',\n",
       " 'Olaparib, Sapacitabine',\n",
       " 'BI 860585',\n",
       " 'ONM 100',\n",
       " 'TriMix-MEL',\n",
       " 'Camidanlumab tesirine',\n",
       " 'Paclitaxel, Pertuzumab, Trastuzumab',\n",
       " 'Gancotamab',\n",
       " 'Eflapegrastim',\n",
       " 'FLT-3 ligand, Pembrolizumab, Poly ICLC',\n",
       " 'Selinexor',\n",
       " 'Cofetuzumab pelidotin',\n",
       " 'Cabozantinib',\n",
       " 'PVX 410',\n",
       " 'PLX 51107',\n",
       " 'Imiquimod',\n",
       " 'Balixafortide',\n",
       " 'Avelumab',\n",
       " 'Ifetroban',\n",
       " 'SpagoPix',\n",
       " 'Pertuzumab, Trastuzumab, Trastuzumab emtansine',\n",
       " 'Bevacizumab, Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel',\n",
       " 'ABBV 181, ABBV 368',\n",
       " 'Gallium 68 satoreotide',\n",
       " 'Lasofoxifene',\n",
       " 'Selumetinib, Vistusertib',\n",
       " 'Fluciclovine 18F',\n",
       " 'Pamiparib, Temozolomide',\n",
       " 'Cediranib, Durvalumab, Olaparib',\n",
       " 'MCLA 128',\n",
       " 'Enzalutamide, Fulvestrant',\n",
       " 'Degarelix',\n",
       " 'Anastrozole, Zoledronic acid',\n",
       " 'RX 5902',\n",
       " 'SC-005',\n",
       " 'Cyclophosphamide, Indometacin, IRX 2, Multivitamin, Omeprazole, Zinc',\n",
       " 'GSK 3326595',\n",
       " '9-ING-41, Carboplatin, Doxorubicin, Gemcitabine, Lomustine, Paclitaxel',\n",
       " 'Copanlisib',\n",
       " 'Asparaginase, Carboplatin, Gemcitabine',\n",
       " 'Ferumoxytol, Irinotecan',\n",
       " 'BAT 8003',\n",
       " 'Azacitidine',\n",
       " 'LY 3300054, Necitumumab, Ramucirumab',\n",
       " 'Abemaciclib, Fulvestrant, Trastuzumab',\n",
       " 'AVX 901, Pembrolizumab',\n",
       " 'Capecitabine, Darolutamide',\n",
       " 'Doxorubicin, Gemcitabine, Paclitaxel',\n",
       " 'ARV 471',\n",
       " 'Rivoceranib',\n",
       " 'MK 2206',\n",
       " 'Capecitabine, Paclitaxel, Vinorelbine, ZW 25',\n",
       " 'Pertuzumab, Trastuzumab, Trastuzumab',\n",
       " 'Hydroxychloroquine, Letrozole, Palbociclib',\n",
       " 'Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab',\n",
       " 'Olaparib, Vorinostat',\n",
       " 'Capecitabine, Entinostat',\n",
       " 'Spartalizumab',\n",
       " 'Spartalizumab, WNT 974',\n",
       " 'Eftilagimod alpha',\n",
       " 'Goserelin',\n",
       " 'GX I7, GX I7',\n",
       " 'Atezolizumab, Bevacizumab, Cobimetinib, Ipatasertib',\n",
       " 'BAT 8001',\n",
       " 'Nelipepimut-S, Sargramostim, Trastuzumab',\n",
       " 'Tislelizumab',\n",
       " 'Capecitabine/cyclophosphamide',\n",
       " 'Pamiparib, Tislelizumab',\n",
       " 'Tinostamustine',\n",
       " 'Everolimus, Trastuzumab',\n",
       " 'Bevacizumab, Erlotinib, Paclitaxel',\n",
       " 'Sapanisertib',\n",
       " 'Sonidegib',\n",
       " 'Denileukin diftitox',\n",
       " 'INT 230-6',\n",
       " 'Carboplatin, Paclitaxel',\n",
       " 'Anti-Cd7 CAR-NK cells',\n",
       " 'BI 836880',\n",
       " 'Plasmodium vivax immunotherapy',\n",
       " 'Anti-MUC1 CAR-T cell therapy',\n",
       " 'Tegafur/uracil',\n",
       " 'Lapatinib, Vinorelbine',\n",
       " 'Letrozole, Vinorelbine',\n",
       " 'Gimeracil/oteracil/tegafur',\n",
       " 'Nivolumab, Pembrolizumab',\n",
       " 'Rivoceranib, Vinorelbine',\n",
       " 'Lapatinib, Trastuzumab emtansine',\n",
       " 'Exemestane, Goserelin',\n",
       " 'Anastrozole, Saracatinib',\n",
       " 'Durvalumab, Ganetespib, Ganitumab, Ladiratuzumab-Vedotin, MK 2206, Neratinib, Olaparib, Patritumab, Pembrolizumab, Pertuzumab, SD 101 Dynavax, Talazoparib, Trastuzumab, Trebananib, Veliparib',\n",
       " 'Anastrozole, Pictrelisib',\n",
       " 'Telapristone',\n",
       " 'Docetaxel, Pertuzumab, Trastuzumab',\n",
       " 'R 763',\n",
       " 'Cetuximab',\n",
       " 'Pembrolizumab, RX 5902',\n",
       " 'Merestinib',\n",
       " 'Paclitaxel, Pembrolizumab',\n",
       " 'ABBV 176',\n",
       " 'Megestrol',\n",
       " 'Itacitinib, Parsaclisib',\n",
       " 'Carboplatin, Doxorubicin liposomal, Ferric carboxymaltose, Paclitaxel, Pertuzumab, Trastuzumab',\n",
       " 'Imatinib, Letrozole',\n",
       " 'CYAD 01',\n",
       " 'Ramucirumab',\n",
       " 'Epirubicin, Paclitaxel',\n",
       " 'Capecitabine, Paclitaxel',\n",
       " 'Paclitaxel, Phenelzine',\n",
       " 'SGMIB anti-HER2 monoclonal antibody I-131',\n",
       " 'RAD 140',\n",
       " 'Anastrozole, Palbociclib',\n",
       " 'Monoclonal antibody 3S193',\n",
       " 'Atezolizumab, PRS 343',\n",
       " 'Carboplatin, Pembrolizumab',\n",
       " 'Avelumab, Palbociclib, Tamoxifen',\n",
       " 'Idronoxil',\n",
       " 'GX I7, Pembrolizumab',\n",
       " 'BAY 1217389, BAY 1217389',\n",
       " 'AK 01',\n",
       " 'AE 37, Pembrolizumab',\n",
       " 'INO 1400, INO 9012',\n",
       " 'Everolimus, Letrozole',\n",
       " 'Pembrolizumab, Pexidartinib',\n",
       " 'IVAC-M-uID, IVAC-W-bre1-uID',\n",
       " 'Decitabine, Pembrolizumab',\n",
       " 'Mirvetuximab soravtansine',\n",
       " 'AZD 6738, Durvalumab, Olaparib',\n",
       " 'Doxorubicin liposomal, Gemcitabine',\n",
       " 'Docetaxel, Everolimus',\n",
       " 'Ipilimumab, LTX 315, Pembrolizumab',\n",
       " 'INB 03',\n",
       " 'Niraparib',\n",
       " 'PEN 866',\n",
       " 'Fulvestrant, Ribociclib, Spartalizumab',\n",
       " 'Leuprorelin',\n",
       " 'Capecitabine, Pyrotinib',\n",
       " 'Enobosarm, Pembrolizumab',\n",
       " 'Bendamustine',\n",
       " 'Docetaxel, Pyrotinib, Trastuzumab',\n",
       " 'Birabresib',\n",
       " 'AB-928, GLS 010, IPI 549',\n",
       " 'BT 1718',\n",
       " 'Trastuzumab, Tucatinib',\n",
       " 'Letrozole, Palbociclib, Tucatinib',\n",
       " 'ERY-ASP',\n",
       " 'Cisplatin, Cyclophosphamide, Etoposide, Filgrastim',\n",
       " 'Pimasertib, Voxtalisib',\n",
       " 'Trastuzumab emtansine, Vinorelbine',\n",
       " 'AutoSynVax, QS 21',\n",
       " 'Fulvestrant, Goserelin, Palbociclib',\n",
       " 'Atezolizumab, Cyclophosphamide, Doxorubicin liposomal',\n",
       " 'Atezolizumab, CPI 444',\n",
       " 'T-lymphocyte cell therapy',\n",
       " 'Aldoxorubicin, ALT 803, Avelumab, Brachyury peptide vaccine, CD16 and interleukin 2 expressing natural killer cells-NantKwest, Cyclophosphamide, ETBX 011, ETBX-051, ETBX-061, Fluorouracil, Folinic acid, GI 4000, GI 6207, Paclitaxel',\n",
       " 'Eribulin, Pertuzumab, Trastuzumab, Trastuzumab emtansine',\n",
       " 'COTI 2, Eribulin',\n",
       " 'Atezolizumab, Entinostat',\n",
       " 'Omega-3-acid ethyl esters, Raloxifene',\n",
       " 'Fulvestrant, Tipifarnib',\n",
       " 'NIS 793, Spartalizumab',\n",
       " 'Aglatimagene besadenovec, Pembrolizumab, Valaciclovir',\n",
       " 'Carboplatin, Cetuximab, Irinotecan',\n",
       " 'Gadobutrol',\n",
       " 'Perflubutane',\n",
       " 'Ulipristal',\n",
       " 'Tilarginine',\n",
       " 'Cytarabine',\n",
       " 'Cyclophosphamide, Paclitaxel, Trastuzumab',\n",
       " 'Doxorubicin, Tumour cells apoptosis factor',\n",
       " 'Molibresib',\n",
       " 'Leflunomide',\n",
       " 'Letrozole, Palbociclib, Trastuzumab emtansine',\n",
       " 'ADCT 502',\n",
       " 'Doxorubicin',\n",
       " 'Cyclophosphamide, Docetaxel, Epirubicin',\n",
       " 'Enzalutamide, Trastuzumab',\n",
       " 'Pembrolizumab, Tomivosertib',\n",
       " 'Balixafortide, Eribulin',\n",
       " 'AZD 6738',\n",
       " 'Docetaxel, Epirubicin',\n",
       " 'Taladegib',\n",
       " 'Letrozole, Triptorelin, Zoledronic acid',\n",
       " 'Durvalumab, Paclitaxel',\n",
       " 'Ilodecakin',\n",
       " 'Lucitanib',\n",
       " 'Letrozole, Palbociclib, Pembrolizumab',\n",
       " 'Pamiparib',\n",
       " 'AZD-8186, Vistusertib',\n",
       " 'ODM 203',\n",
       " 'Crizotinib',\n",
       " 'Carboplatin, Durvalumab, Gemcitabine, Paclitaxel, Peptide vaccines, Poly ICLC',\n",
       " 'NEO201',\n",
       " 'Gemcitabine, Paclitaxel',\n",
       " 'Durvalumab, Neoantigen DNA vaccine MedImmune/Washington University School of Medicine',\n",
       " 'ARRY 382, Pembrolizumab',\n",
       " 'Estradiol, Exemestane',\n",
       " 'Romidepsin',\n",
       " 'Atezolizumab, Ipatasertib',\n",
       " 'TPIV 110',\n",
       " 'TPIV 110, Trastuzumab',\n",
       " 'Carboplatin, Docetaxel',\n",
       " 'Capecitabine, Rivoceranib',\n",
       " 'TPIV 200',\n",
       " 'Bicalutamide',\n",
       " 'Docetaxel, Ixabepilone',\n",
       " 'Capecitabine, Paclitaxel, Trastuzumab',\n",
       " 'Pemigatinib',\n",
       " 'Gedatolisib, Trastuzumab',\n",
       " 'Lacnotuzumab, Spartalizumab',\n",
       " '2 fluorofucose',\n",
       " 'PKI 179',\n",
       " 'Leuprorelin, Toremifene',\n",
       " 'Olaparib, Palbociclib',\n",
       " 'Talazoparib, Telaglenastat',\n",
       " 'Darolutamide',\n",
       " 'Atezolizumab, Carboplatin',\n",
       " 'SCT 200',\n",
       " 'Capecitabine, Trastuzumab',\n",
       " 'Alisertib, Fulvestrant',\n",
       " 'CD40 ligand MUC1 loaded dendritic cell vaccine',\n",
       " 'Gemcitabine, Pertuzumab, Trastuzumab',\n",
       " 'BMS-986277, Nivolumab',\n",
       " 'Carboplatin, Nivolumab',\n",
       " 'Copanlisib, Letrozole, Palbociclib',\n",
       " 'Neratinib, Temsirolimus',\n",
       " 'Benegrastim',\n",
       " 'Fulvestrant, Olaparib, Palbociclib',\n",
       " 'SCO-101',\n",
       " 'Samarium 153 lexidronam',\n",
       " 'Bevacizumab, Doxorubicin, Everolimus',\n",
       " 'Vocimagene amiretrorepvec-flucytosine gene therapy, Vocimagene amiretrorepvec-flucytosine gene therapy, Vocimagene amiretrorepvec-flucytosine gene therapy, Vocimagene amiretrorepvec-flucytosine gene therapy',\n",
       " 'Fulvestrant, Ixazomib',\n",
       " 'Etoposide, Rivoceranib',\n",
       " 'Afimoxifene',\n",
       " 'Letrozole, Pertuzumab, Trastuzumab',\n",
       " 'Pembrolizumab, Trastuzumab-deruxtecan',\n",
       " 'Enzalutamide, Paclitaxel',\n",
       " 'BIL 06v',\n",
       " 'IAB 22M2C',\n",
       " 'Sapitinib',\n",
       " 'Napabucasin',\n",
       " 'LCL 161',\n",
       " 'Dendritic cell vaccines, Trastuzumab, Vinorelbine',\n",
       " 'Pexastimogene devacirepvec',\n",
       " 'MEDI 4276',\n",
       " 'ETBX 021',\n",
       " 'Pelareorep',\n",
       " 'Mifepristone, Paclitaxel',\n",
       " 'Atezolizumab, Pelareorep',\n",
       " 'Reparixin',\n",
       " 'Eribulin, Everolimus',\n",
       " 'Dexamethasone, Everolimus, Letrozole',\n",
       " 'Alpelisib, Ganitumab',\n",
       " 'Dovitinib',\n",
       " 'Anastrozole, Goserelin, Tamoxifen',\n",
       " 'Anti HER2 small molecule imaging agent',\n",
       " 'Bintrafusp alfa, Eribulin',\n",
       " 'Mogamulizumab',\n",
       " 'NUC 1031',\n",
       " 'Pemetrexed, Sorafenib',\n",
       " 'AUS 131',\n",
       " 'BLEX 404',\n",
       " 'Cyclophosphamide, Motolimod',\n",
       " 'Cabozantinib, Trastuzumab',\n",
       " 'TT-00420',\n",
       " 'Adalimumab',\n",
       " 'Bicalutamide, Ipilimumab, Nivolumab',\n",
       " 'Capecitabine, Radium 223 chloride',\n",
       " 'Cisplatin, Everolimus, Paclitaxel',\n",
       " 'Carboplatin, Paclitaxel, Pembrolizumab',\n",
       " 'Durvalumab, Tremelimumab, Vinorelbine',\n",
       " 'Carboplatin, Paclitaxel, Rivoceranib',\n",
       " 'Epertinib',\n",
       " 'Interferon gamma-1b',\n",
       " 'SGN-1, SGN-1',\n",
       " 'Orantinib',\n",
       " 'Dusigitumab',\n",
       " 'Cabozantinib, Nivolumab',\n",
       " 'Paclitaxel, Pegfilgrastim, Trastuzumab, Trastuzumab',\n",
       " 'Onapristone',\n",
       " 'SAR 428926',\n",
       " 'Mitoxantrone liposomal',\n",
       " 'Paclitaxel, Trastuzumab',\n",
       " 'G1T-48, Lerociclib',\n",
       " 'MEDI 6469',\n",
       " 'Lacnotuzumab',\n",
       " 'Capivasertib, Vistusertib',\n",
       " 'Dalotuzumab',\n",
       " 'Rogaratinib',\n",
       " 'Copanlisib, Fulvestrant, Palbociclib',\n",
       " 'Enoblituzumab',\n",
       " 'Paclitaxel, Trastuzumab, TVB 2640',\n",
       " 'Cisplatin, Paclitaxel',\n",
       " 'Lapatinib, Veliparib',\n",
       " 'Bevacizumab, Docetaxel',\n",
       " 'Buparlisib, Olaparib',\n",
       " 'IMM 101',\n",
       " 'Carboplatin, Doxorubicin liposomal, Paclitaxel',\n",
       " 'Bevacizumab, Docetaxel, Trastuzumab',\n",
       " 'INXN 2001, Palifosfamide, Veledimex',\n",
       " 'Capecitabine, Epirubicin',\n",
       " 'TTC 352',\n",
       " 'Crizotinib, Fulvestrant',\n",
       " 'Prexigebersen',\n",
       " 'Capecitabine, Everolimus, Lapatinib',\n",
       " 'TAS-0728',\n",
       " 'Doxorubicin liposomal, Pembrolizumab',\n",
       " 'Ruxolitinib, Trastuzumab',\n",
       " 'Pertuzumab, Taxanes, Trastuzumab',\n",
       " 'Abemaciclib, Abemaciclib',\n",
       " 'Bicalutamide, Palbociclib',\n",
       " 'Aldoxorubicin, ALT 803, Avelumab, Bevacizumab, Brachyury peptide vaccine, Capecitabine, CST 101, Cyclophosphamide, ETBX 011, ETBX-051, ETBX-061, Fluorouracil, Folinic acid, GI 4000, GI 6207, Omega-3-acid ethyl esters, Oxaliplatin, Paclitaxel',\n",
       " 'Pertuzumab, Ribociclib, Trastuzumab',\n",
       " 'Depoxythilone',\n",
       " 'Relacorilant',\n",
       " 'Eftilagimod alpha, Paclitaxel',\n",
       " 'Lapatinib, Paclitaxel, Trastuzumab emtansine',\n",
       " 'Cetuximab, Ixabepilone',\n",
       " 'Elgemtumab, Trastuzumab',\n",
       " 'Deslorelin, Estradiol, Testosterone',\n",
       " 'SHR 9549',\n",
       " 'Durvalumab, Sacituzumab govitecan',\n",
       " 'OBI 833',\n",
       " 'Anastrozole, Pazopanib',\n",
       " 'Cancer vaccine MUC-1, Poly ICLC',\n",
       " 'Adavosertib, Cisplatin',\n",
       " 'Sapanisertib, Tamoxifen',\n",
       " 'Dalotuzumab, Ridaforolimus',\n",
       " 'Glembatumumab vedotin, Ipilimumab, Nivolumab',\n",
       " 'Fulvestrant, Goserelin',\n",
       " 'Nivolumab, Rivoceranib',\n",
       " 'Tasisulam',\n",
       " 'Mirvetuximab soravtansine, Rucaparib',\n",
       " 'Rucaparib, Rucaparib',\n",
       " 'EOC 317',\n",
       " 'BLZ 945, Spartalizumab',\n",
       " 'Alpelisib, Elgemtumab, Trastuzumab',\n",
       " 'ALT-P7',\n",
       " 'Alpelisib, Buparlisib, Ribociclib',\n",
       " 'Pyrotinib',\n",
       " 'Carboplatin, Paclitaxel, Pazopanib',\n",
       " 'Capecitabine, Docetaxel, Letrozole, Tamoxifen',\n",
       " 'DPX 0907',\n",
       " 'AE 37, HER2/Neu GP2 peptide vaccine NuGenerex Immuno-Oncology',\n",
       " 'V3-MOMMO',\n",
       " 'Ciclosporin, Cyclophosphamide, Fludarabine, Mycophenolate mofetil, Mycophenolate mofetil',\n",
       " 'Capecitabine, Doxorubicin',\n",
       " 'TPI 287',\n",
       " 'Nintedanib',\n",
       " 'Anastrozole, Exemestane, Fulvestrant, Letrozole, Paclitaxel, Talimogene laherparepvec, Tamoxifen',\n",
       " 'OBI 888',\n",
       " 'Adagloxad simolenin',\n",
       " 'Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine, Durvalumab',\n",
       " 'D 0502, Palbociclib',\n",
       " 'Atezolizumab, Cobimetinib, Idasanutlin',\n",
       " 'Darbepoetin alfa',\n",
       " 'Lapatinib, Paclitaxel, Trastuzumab',\n",
       " 'Everolimus, LCL 161, Panobinostat, Spartalizumab',\n",
       " '2X 121',\n",
       " 'SM 88',\n",
       " 'Fulvestrant, Palbociclib, Pertuzumab, Trastuzumab',\n",
       " 'VMD-928',\n",
       " 'SM 88, SM 88',\n",
       " 'Letrozole, Sorafenib',\n",
       " 'Pertuzumab, Pertuzumab, Trastuzumab, Trastuzumab',\n",
       " 'Cixutumumab, Temsirolimus',\n",
       " 'Everolimus, Lapatinib, Letrozole',\n",
       " 'Patritumab',\n",
       " 'Filgrastim, Pegfilgrastim',\n",
       " 'Regorafenib, Tipiracil/trifluridine',\n",
       " 'Entinostat, Exemestane',\n",
       " 'Docetaxel, Rivoceranib',\n",
       " 'Tamoxifen',\n",
       " 'Lenvatinib, Letrozole',\n",
       " 'Bevacizumab, Eribulin',\n",
       " 'MVA-p53',\n",
       " 'Falimarev, Inalimarev',\n",
       " 'Sunitinib',\n",
       " 'Docetaxel, Sunitinib',\n",
       " 'Fluorouracil, Gimeracil/oteracil/tegafur',\n",
       " 'Durvalumab, Eribulin',\n",
       " 'Nivolumab, RGX 104',\n",
       " 'Tecemotide',\n",
       " 'Paclitaxel, Ricolinostat',\n",
       " 'Everolimus, Exemestane, Palbociclib',\n",
       " 'Cyclophosphamide, Epirubicin, Paclitaxel',\n",
       " 'Bevacizumab, Carboplatin, Gemcitabine',\n",
       " 'Cabazitaxel',\n",
       " 'Exemestane, Triptorelin',\n",
       " 'Niraparib, Pembrolizumab',\n",
       " 'Denosumab, Radium 223 chloride',\n",
       " 'Durvalumab, Ibrutinib',\n",
       " 'Bevacizumab, Capecitabine, Oxaliplatin',\n",
       " 'AL 101',\n",
       " 'Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Gemcitabine, Zoledronic acid',\n",
       " 'Cyclophosphamide, Doxorubicin, Glembatumumab vedotin',\n",
       " '18F DCFPyL',\n",
       " 'Tomivosertib',\n",
       " 'GSK 3174998, Pembrolizumab',\n",
       " 'Doxorubicin liposomal, Paclitaxel',\n",
       " 'GBR 1302',\n",
       " 'Zibotentan',\n",
       " 'Trodusquemine',\n",
       " 'Tamoxifen, Vorinostat',\n",
       " 'Bevacizumab, Everolimus, Lapatinib',\n",
       " 'Docetaxel, Imatinib',\n",
       " 'Breast cancer vaccine, Trastuzumab',\n",
       " 'Brilanestrant, Pravastatin',\n",
       " 'Perflutren',\n",
       " 'Gemcitabine, Genistein',\n",
       " 'Anti CD3 MUC1 bispecific antibody Benhealth Biopharmaceutical',\n",
       " 'Binimetinib',\n",
       " '852A',\n",
       " 'Brostallicin, Cisplatin',\n",
       " 'Pixantrone',\n",
       " 'Docetaxel, Endostatin, Epirubicin',\n",
       " 'Lapatinib, Pertuzumab, Trastuzumab',\n",
       " 'Fludeoxyglucose F-18, Flutemetamol-F-18',\n",
       " 'Ubidecarenone',\n",
       " 'MK 0752',\n",
       " 'Emactuzumab, Selicrelumab',\n",
       " 'Carboplatin, Paclitaxel, Panitumumab',\n",
       " 'Crizotinib, Dasatinib',\n",
       " 'Atezolizumab, Varlilumab',\n",
       " 'Defactinib',\n",
       " 'IMP 4297',\n",
       " 'Tremelimumab',\n",
       " 'Dinaciclib, Pembrolizumab',\n",
       " 'Capecitabine, Trastuzumab emtansine',\n",
       " 'Anastrozole, Testosterone',\n",
       " 'Anastrozole, Enobosarm',\n",
       " 'Azacitidine, Entinostat',\n",
       " 'Neratinib, Trastuzumab',\n",
       " 'Anti-CD3-anti-HER2-activated T-cells',\n",
       " 'Fulvestrant, Fulvestrant',\n",
       " 'BR-55',\n",
       " 'AdVEGF-Herantis',\n",
       " 'Choriogonadotropin alfa',\n",
       " 'Folate-fluorescein isothiocyanate conjugate',\n",
       " 'Pembrolizumab, PVX 410',\n",
       " 'Anastrozole, Goserelin',\n",
       " 'BMS 986115',\n",
       " 'Ixabepilone, Vorinostat',\n",
       " 'Verteporfin',\n",
       " 'Eribulin, Lenvatinib',\n",
       " 'Ibrutinib',\n",
       " 'Belinostat, Carfilzomib, Daratumumab, Fludeoxyglucose F-18, Nivolumab, Obinutuzumab, Pembrolizumab, Rituximab, Romidepsin, Trastuzumab',\n",
       " 'TDM 812',\n",
       " 'SCMod1',\n",
       " 'Dinaciclib',\n",
       " 'AVX 901',\n",
       " 'Uprosertib',\n",
       " 'Losatuxizumab-vedotin',\n",
       " 'Cyclophosphamide, Docetaxel, Doxorubicin',\n",
       " 'Propagermanium',\n",
       " 'Fresolimumab',\n",
       " 'Emactuzumab',\n",
       " 'Capecitabine, Cyclophosphamide, Vinorelbine',\n",
       " 'Capecitabine, Pembrolizumab',\n",
       " 'ADXS 31164',\n",
       " 'Capecitabine, Docetaxel',\n",
       " 'Minnelide',\n",
       " 'ARX 788',\n",
       " 'BCD 115',\n",
       " 'Orteronel',\n",
       " 'Tesevatinib',\n",
       " 'Valproic acid',\n",
       " 'Lapatinib, Paclitaxel',\n",
       " 'Zafirlukast',\n",
       " 'Docosahexaenoic acid',\n",
       " '212 Pb TCMC trastuzumab',\n",
       " 'Mifepristone, Pembrolizumab',\n",
       " 'Aderbasib, Docetaxel, Trastuzumab',\n",
       " 'Ispinesib',\n",
       " 'Capecitabine, Digoxin',\n",
       " 'Gemcitabine, Mirvetuximab soravtansine',\n",
       " 'Zoptarelin doxorubicin',\n",
       " 'Nivolumab, Rucaparib',\n",
       " 'GDC 0575',\n",
       " 'Eribulin, Taxanes',\n",
       " 'RG 6047',\n",
       " 'PF 6664178',\n",
       " 'Bevacizumab, Cyclophosphamide, Paclitaxel',\n",
       " 'Panitumumab',\n",
       " 'Sapanisertib, Serabelisib',\n",
       " 'Cofetuzumab pelidotin, Gedatolisib',\n",
       " 'Gimeracil/oteracil/tegafur, Lapatinib',\n",
       " 'Lipegfilgrastim',\n",
       " 'Fluorouracil, Folinic acid, Oxaliplatin',\n",
       " 'IMC CS4',\n",
       " 'Gancotamab, Trastuzumab',\n",
       " 'Odanacatib',\n",
       " 'Selumetinib',\n",
       " 'Aflibercept, Capecitabine',\n",
       " 'Endoxifen, Endoxifen',\n",
       " 'Brachyury peptide vaccine',\n",
       " 'Trastuzumab, Trastuzumab emtansine, Utomilumab',\n",
       " 'Refametinib, Regorafenib',\n",
       " 'Telapristone, Telapristone',\n",
       " 'Vantictumab',\n",
       " 'GALE 301, GALE 302',\n",
       " 'Gemcitabine, Tipifarnib',\n",
       " 'Goserelin, Ribociclib, Tamoxifen',\n",
       " 'Capecitabine, Gimeracil/oteracil/tegafur',\n",
       " 'Raloxifene',\n",
       " 'Poly ICLC',\n",
       " 'Carboplatin, Paclitaxel, Trastuzumab',\n",
       " 'Cyclophosphamide, Cyclophosphamide, Doxorubicin, Paclitaxel, Pegfilgrastim',\n",
       " 'INCB 47986',\n",
       " 'Irinotecan, Trastuzumab',\n",
       " 'Icotinib',\n",
       " 'Fluorouracil/folinic-acid',\n",
       " 'Lumretuzumab',\n",
       " 'Acolbifene',\n",
       " 'CVA 21',\n",
       " 'Dasatinib, Zoledronic acid',\n",
       " 'Oxaliplatin',\n",
       " 'Gemcitabine, Pembrolizumab',\n",
       " 'Capecitabine, Lapatinib, Trastuzumab',\n",
       " 'Cabergoline',\n",
       " 'Imiquimod, Paclitaxel',\n",
       " 'Anakinra',\n",
       " 'Pasireotide',\n",
       " 'Anastrozole, Goserelin, Palbociclib',\n",
       " 'Cyclophosphamide, Dexamethasone, Docetaxel, Doxorubicin, Filgrastim, Lapatinib, Pegfilgrastim, Trastuzumab',\n",
       " 'Ibrutinib, Trastuzumab',\n",
       " 'Doxorubicin liposomal, Veliparib',\n",
       " 'Afatinib, Trastuzumab',\n",
       " 'Anastrozole, Everolimus, Fulvestrant',\n",
       " 'Propranolol',\n",
       " 'Finasteride',\n",
       " 'CT-7001',\n",
       " 'ENMD 2076',\n",
       " 'Doxorubicin liposomal, Paclitaxel, Pertuzumab, Trastuzumab',\n",
       " 'Toremifene',\n",
       " 'Litronesib',\n",
       " 'Everolimus, Niraparib',\n",
       " 'Imatinib',\n",
       " 'Cancer vaccine MUC-1',\n",
       " 'Glutathione/cisplatin, Glutathione/cisplatin',\n",
       " 'Tamoxifen, Toremifene',\n",
       " 'Navitoclax',\n",
       " 'Clodronic acid',\n",
       " 'Denosumab, Zoledronic acid',\n",
       " 'PM 060184',\n",
       " 'GSK 2636771',\n",
       " 'Letrozole, Leuprorelin',\n",
       " 'Bevacizumab, Capecitabine, Everolimus, Exemestane',\n",
       " 'Lapatinib, Lapatinib',\n",
       " 'Trametinib, Uprosertib',\n",
       " 'Afuresertib, Trametinib',\n",
       " 'Capecitabine, Doxorubicin liposomal',\n",
       " 'Carboplatin, Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab',\n",
       " 'INO 1400',\n",
       " 'Irinotecan',\n",
       " 'Gemcitabine, Lapatinib',\n",
       " 'ALT 803, Avelumab, Bevacizumab, Brachyury peptide vaccine, CST 101, ETBX 011, ETBX-051, ETBX-061, GI 4000, GI 6207, Omega-3-acid ethyl esters',\n",
       " 'Autologous formalin-fixed tumour cell vaccine',\n",
       " 'Doxorubicin, Paclitaxel, Trastuzumab',\n",
       " 'Cisplatin, Veliparib, Vinorelbine',\n",
       " 'Ritonavir',\n",
       " 'Hemay 022',\n",
       " 'Indatuximab ravtansine',\n",
       " 'Galunisertib, Paclitaxel',\n",
       " 'Upamostat',\n",
       " 'Carboplatin, Eribulin, Veliparib',\n",
       " 'PF 6650808',\n",
       " 'Bortezomib',\n",
       " 'Anastrozole, Entinostat',\n",
       " 'Icrucumab, Ramucirumab',\n",
       " 'Antineoplaston-A10, Antineoplaston-AS2-1',\n",
       " 'Polysaccharide K',\n",
       " 'Vinflunine',\n",
       " 'Monoclonal antibody F16 I 131',\n",
       " 'F-18 fluorothymidine',\n",
       " 'Polyphenon E',\n",
       " 'Calcifediol',\n",
       " 'Docetaxel, Paclitaxel',\n",
       " 'Masitinib',\n",
       " 'Bevacizumab, Capecitabine, Gemcitabine',\n",
       " 'Bevacizumab, Carboplatin, Paclitaxel',\n",
       " 'Lenalidomide',\n",
       " 'Tigatuzumab',\n",
       " 'Trastuzumab, Trastuzumab, Trastuzumab',\n",
       " 'Elgemtumab',\n",
       " 'Conjugated estrogens, Conjugated estrogens/medroxyprogesterone',\n",
       " 'Ixabepilone, Pazopanib',\n",
       " ...]"
      ]
     },
     "execution_count": 185,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "unique_drugs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-11T23:32:47.747816Z",
     "start_time": "2019-03-11T23:32:47.694901Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Trial ID</th>\n",
       "      <th>Trial Title</th>\n",
       "      <th>Mechanism of action</th>\n",
       "      <th>Drug class (therapeutic effect)</th>\n",
       "      <th>Drug class (chemical)</th>\n",
       "      <th>Drug class (biological)</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Organisations</th>\n",
       "      <th>Trial Design</th>\n",
       "      <th>Trial Endpoints</th>\n",
       "      <th>...</th>\n",
       "      <th>Trial End date</th>\n",
       "      <th>Trial Status</th>\n",
       "      <th>Trial History</th>\n",
       "      <th>Diseases treated</th>\n",
       "      <th>Biomarkers-Inclusion</th>\n",
       "      <th>Biomarkers-Exclusion</th>\n",
       "      <th>Biomarkers-Outcome Measure</th>\n",
       "      <th>Biomarkers-Safety</th>\n",
       "      <th>Biomarkers-not specified</th>\n",
       "      <th>Primary Drugs</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>700240183</td>\n",
       "      <td>A Phase 1b, Open-label Study to Assess the Saf...</td>\n",
       "      <td>Antibody-dependent cell cytotoxicity, Antimeta...</td>\n",
       "      <td>Antineoplastics, Antineoplastics, Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>Monoclonal antibodies</td>\n",
       "      <td>Advanced breast cancer, Male breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>multicentre, open, parallel, prospective</td>\n",
       "      <td>Incidence of adverse events\\ntime_frame: Up to...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Jul 2019 (planned)</td>\n",
       "      <td>Active, no longer recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Advanced breast cancer|treatment|second-line o...</td>\n",
       "      <td>HER2</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>700257487</td>\n",
       "      <td>Phase 2 Randomized, Double-Blinded, Controlled...</td>\n",
       "      <td>Antibody-dependent cell cytotoxicity, Antibody...</td>\n",
       "      <td>Antineoplastics, Antineoplastics, Antineoplast...</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>Monoclonal antibodies, Monoclonal antibodies</td>\n",
       "      <td>Advanced breast cancer, Carcinoma, Male breast...</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>double-blind, multicentre, parallel, prospecti...</td>\n",
       "      <td>Progression-free survival (PFS) per RECIST 1.1...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Jul 2021 (planned)</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Advanced breast cancer|treatment|second-line o...</td>\n",
       "      <td>HER2</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>700304216</td>\n",
       "      <td>A Phase 1, Open-Label, Fixed-Sequence, Drug-Dr...</td>\n",
       "      <td>AMP activated protein kinase stimulants, Emiss...</td>\n",
       "      <td>Antineoplastics, Antihyperglycaemics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer, Colorectal cancer</td>\n",
       "      <td>Seattle Genetics, Seattle Genetics</td>\n",
       "      <td>open, prospective</td>\n",
       "      <td>Maximum observed plasma concentration (Cmax) o...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Mar 2019 (planned)</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Breast cancer|treatment|; Colorectal cancer|tr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>478</th>\n",
       "      <td>700302859</td>\n",
       "      <td>A Phase 1, Randomized, Partially Double-Blind,...</td>\n",
       "      <td>DNA gyrase inhibitors, ERBB 2 receptor antagon...</td>\n",
       "      <td>Antineoplastics, Antibacterials</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer, Colorectal cancer</td>\n",
       "      <td>Seattle Genetics, Seattle Genetics</td>\n",
       "      <td>crossover, double-blind, prospective, randomised</td>\n",
       "      <td>Placebo-corrected change-from-baseline in QTcF...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Mar 2019 (planned)</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>2019-02-03|Other trial event|Last checked agai...</td>\n",
       "      <td>Breast cancer|treatment|; Colorectal cancer|tr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>481</th>\n",
       "      <td>700238859</td>\n",
       "      <td>A Phase 1b, Open-label Study to Assess the Saf...</td>\n",
       "      <td>Apoptosis stimulants, ERBB 2 receptor antagoni...</td>\n",
       "      <td>Antineoplastics, Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>Immunoconjugates, Immunotoxins, Monoclonal ant...</td>\n",
       "      <td>Advanced breast cancer, Male breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>multicentre, open, prospective</td>\n",
       "      <td>Incidence and severity of adverse events\\nsafe...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Jul 2019 (planned)</td>\n",
       "      <td>Active, no longer recruiting</td>\n",
       "      <td>2019-02-01|Other trial event|Last checked agai...</td>\n",
       "      <td>Advanced breast cancer|treatment|stage IV; Mal...</td>\n",
       "      <td>HER2</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>489</th>\n",
       "      <td>700301177</td>\n",
       "      <td>An Open-label, Non-randomized, Single-dose, Pa...</td>\n",
       "      <td>ERBB 2 receptor antagonists</td>\n",
       "      <td>Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer, Colorectal cancer</td>\n",
       "      <td>Seattle Genetics, Seattle Genetics</td>\n",
       "      <td>multicentre, open, parallel, prospective</td>\n",
       "      <td>Maximum observed concentration\\ndescription: P...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 May 2019 (planned)</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>2019-02-01|Other trial event|Last checked agai...</td>\n",
       "      <td>Breast cancer|treatment|; Colorectal cancer|tr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>570</th>\n",
       "      <td>700301239</td>\n",
       "      <td>A Phase 1, Open-Label, Fixed-sequence, 5-part,...</td>\n",
       "      <td>14-alpha demethylase inhibitors, Angiogenesis ...</td>\n",
       "      <td>Antineoplastics, Antihyperlipidaemics, Antifun...</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer, Colorectal cancer</td>\n",
       "      <td>Seattle Genetics, Seattle Genetics</td>\n",
       "      <td>multicentre, open, parallel, prospective</td>\n",
       "      <td>Area under the concentration-time curve (AUC) ...</td>\n",
       "      <td>...</td>\n",
       "      <td>28 Dec 2018 (actual)</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2019-01-22|Other trial event|Last checked agai...</td>\n",
       "      <td>Breast cancer|treatment|; Colorectal cancer|tr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>915</th>\n",
       "      <td>700302217</td>\n",
       "      <td>A Phase 1, Open-label Study of the Absorption,...</td>\n",
       "      <td>ERBB 2 receptor antagonists</td>\n",
       "      <td>Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer, Colorectal cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>open, prospective</td>\n",
       "      <td>Area under the concentration-time curve (AUC) ...</td>\n",
       "      <td>...</td>\n",
       "      <td>30 Jan 2018 (actual)</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2018-12-05|New trial record|New trial record</td>\n",
       "      <td>Breast cancer|treatment|; Colorectal cancer|tr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1507</th>\n",
       "      <td>700026682</td>\n",
       "      <td>A Study of ARRY-380 in Patients With Advanced ...</td>\n",
       "      <td>ERBB 2 receptor antagonists</td>\n",
       "      <td>Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Advanced breast cancer, Bladder cancer, Colore...</td>\n",
       "      <td>Array BioPharma, Array BioPharma</td>\n",
       "      <td>multicentre, open, prospective</td>\n",
       "      <td>Characterize the safety profile of the study d...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Mar 2013 (actual)</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2018-08-31|Biomarker Update|Biomarkers informa...</td>\n",
       "      <td>Advanced breast cancer|treatment|second-line o...</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1760</th>\n",
       "      <td>700292929</td>\n",
       "      <td>Expanded Access Use of Tucatinib for HER2+ Met...</td>\n",
       "      <td>ERBB 2 receptor antagonists</td>\n",
       "      <td>Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics</td>\n",
       "      <td>prospective</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>(planned)</td>\n",
       "      <td>Suspended</td>\n",
       "      <td>2018-04-05|Other trial event|Last checked agai...</td>\n",
       "      <td>Breast cancer|treatment|second-line or greater...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1812</th>\n",
       "      <td>700264999</td>\n",
       "      <td>Phase 3 study of tucatinib (ONT-380) in combin...</td>\n",
       "      <td>Apoptosis stimulants, ERBB 2 receptor antagoni...</td>\n",
       "      <td>Antineoplastics, Antineoplastics</td>\n",
       "      <td>Drug conjugates, Macrolides, Maytansinoids, 2 ...</td>\n",
       "      <td>Immunoconjugates, Immunotoxins, Monoclonal ant...</td>\n",
       "      <td>Breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>prospective</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>(planned)</td>\n",
       "      <td>Planning</td>\n",
       "      <td>2018-03-09|Other trial event|According to a Se...</td>\n",
       "      <td>Breast cancer|treatment|stage IV</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1814</th>\n",
       "      <td>700265020</td>\n",
       "      <td>A phase 2 study of tucatinib (ONT-380) in comb...</td>\n",
       "      <td>Apoptosis stimulants, ERBB 2 receptor antagoni...</td>\n",
       "      <td>Antineoplastics, Antineoplastics</td>\n",
       "      <td>Drug conjugates, Macrolides, Maytansinoids, 2 ...</td>\n",
       "      <td>Immunoconjugates, Immunotoxins, Monoclonal ant...</td>\n",
       "      <td>Breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Seattle Genetics</td>\n",
       "      <td>prospective</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>(planned)</td>\n",
       "      <td>Planning</td>\n",
       "      <td>2018-03-09|Other trial event|According to a Se...</td>\n",
       "      <td>Breast cancer|treatment|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3880</th>\n",
       "      <td>700235510</td>\n",
       "      <td>Proof-of-concept trial of ARRY-380 in patients...</td>\n",
       "      <td>ERBB 2 receptor antagonists</td>\n",
       "      <td>Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Advanced breast cancer, Brain metastases</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics</td>\n",
       "      <td>prospective</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>(planned)</td>\n",
       "      <td>Planning</td>\n",
       "      <td>2013-08-09|New trial record|New trial record</td>\n",
       "      <td>Advanced breast cancer|treatment|; Brain metas...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>13 rows  41 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       Trial ID                                        Trial Title  \\\n",
       "1     700240183  A Phase 1b, Open-label Study to Assess the Saf...   \n",
       "10    700257487  Phase 2 Randomized, Double-Blinded, Controlled...   \n",
       "16    700304216  A Phase 1, Open-Label, Fixed-Sequence, Drug-Dr...   \n",
       "478   700302859  A Phase 1, Randomized, Partially Double-Blind,...   \n",
       "481   700238859  A Phase 1b, Open-label Study to Assess the Saf...   \n",
       "489   700301177  An Open-label, Non-randomized, Single-dose, Pa...   \n",
       "570   700301239  A Phase 1, Open-Label, Fixed-sequence, 5-part,...   \n",
       "915   700302217  A Phase 1, Open-label Study of the Absorption,...   \n",
       "1507  700026682  A Study of ARRY-380 in Patients With Advanced ...   \n",
       "1760  700292929  Expanded Access Use of Tucatinib for HER2+ Met...   \n",
       "1812  700264999  Phase 3 study of tucatinib (ONT-380) in combin...   \n",
       "1814  700265020  A phase 2 study of tucatinib (ONT-380) in comb...   \n",
       "3880  700235510  Proof-of-concept trial of ARRY-380 in patients...   \n",
       "\n",
       "                                    Mechanism of action  \\\n",
       "1     Antibody-dependent cell cytotoxicity, Antimeta...   \n",
       "10    Antibody-dependent cell cytotoxicity, Antibody...   \n",
       "16    AMP activated protein kinase stimulants, Emiss...   \n",
       "478   DNA gyrase inhibitors, ERBB 2 receptor antagon...   \n",
       "481   Apoptosis stimulants, ERBB 2 receptor antagoni...   \n",
       "489                         ERBB 2 receptor antagonists   \n",
       "570   14-alpha demethylase inhibitors, Angiogenesis ...   \n",
       "915                         ERBB 2 receptor antagonists   \n",
       "1507                        ERBB 2 receptor antagonists   \n",
       "1760                        ERBB 2 receptor antagonists   \n",
       "1812  Apoptosis stimulants, ERBB 2 receptor antagoni...   \n",
       "1814  Apoptosis stimulants, ERBB 2 receptor antagoni...   \n",
       "3880                        ERBB 2 receptor antagonists   \n",
       "\n",
       "                        Drug class (therapeutic effect)  \\\n",
       "1     Antineoplastics, Antineoplastics, Antineoplastics   \n",
       "10    Antineoplastics, Antineoplastics, Antineoplast...   \n",
       "16                 Antineoplastics, Antihyperglycaemics   \n",
       "478                     Antineoplastics, Antibacterials   \n",
       "481                    Antineoplastics, Antineoplastics   \n",
       "489                                     Antineoplastics   \n",
       "570   Antineoplastics, Antihyperlipidaemics, Antifun...   \n",
       "915                                     Antineoplastics   \n",
       "1507                                    Antineoplastics   \n",
       "1760                                    Antineoplastics   \n",
       "1812                   Antineoplastics, Antineoplastics   \n",
       "1814                   Antineoplastics, Antineoplastics   \n",
       "3880                                    Antineoplastics   \n",
       "\n",
       "                                  Drug class (chemical)  \\\n",
       "1     2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "10    2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "16    2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "478   2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "481   2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "489   2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "570   2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "915   2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "1507  2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "1760  2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "1812  Drug conjugates, Macrolides, Maytansinoids, 2 ...   \n",
       "1814  Drug conjugates, Macrolides, Maytansinoids, 2 ...   \n",
       "3880  2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "\n",
       "                                Drug class (biological)  \\\n",
       "1                                 Monoclonal antibodies   \n",
       "10         Monoclonal antibodies, Monoclonal antibodies   \n",
       "16                                                  NaN   \n",
       "478                                                 NaN   \n",
       "481   Immunoconjugates, Immunotoxins, Monoclonal ant...   \n",
       "489                                                 NaN   \n",
       "570                                                 NaN   \n",
       "915                                                 NaN   \n",
       "1507                                                NaN   \n",
       "1760                                                NaN   \n",
       "1812  Immunoconjugates, Immunotoxins, Monoclonal ant...   \n",
       "1814  Immunoconjugates, Immunotoxins, Monoclonal ant...   \n",
       "3880                                                NaN   \n",
       "\n",
       "                                             Indication  \\\n",
       "1            Advanced breast cancer, Male breast cancer   \n",
       "10    Advanced breast cancer, Carcinoma, Male breast...   \n",
       "16                     Breast cancer, Colorectal cancer   \n",
       "478                    Breast cancer, Colorectal cancer   \n",
       "481          Advanced breast cancer, Male breast cancer   \n",
       "489                    Breast cancer, Colorectal cancer   \n",
       "570                    Breast cancer, Colorectal cancer   \n",
       "915                    Breast cancer, Colorectal cancer   \n",
       "1507  Advanced breast cancer, Bladder cancer, Colore...   \n",
       "1760                                      Breast cancer   \n",
       "1812                                      Breast cancer   \n",
       "1814                                      Breast cancer   \n",
       "3880           Advanced breast cancer, Brain metastases   \n",
       "\n",
       "                                          Organisations  \\\n",
       "1     Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "10    Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "16                   Seattle Genetics, Seattle Genetics   \n",
       "478                  Seattle Genetics, Seattle Genetics   \n",
       "481   Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "489                  Seattle Genetics, Seattle Genetics   \n",
       "570                  Seattle Genetics, Seattle Genetics   \n",
       "915   Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "1507                   Array BioPharma, Array BioPharma   \n",
       "1760     Cascadian Therapeutics, Cascadian Therapeutics   \n",
       "1812  Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "1814           Cascadian Therapeutics, Seattle Genetics   \n",
       "3880     Cascadian Therapeutics, Cascadian Therapeutics   \n",
       "\n",
       "                                           Trial Design  \\\n",
       "1              multicentre, open, parallel, prospective   \n",
       "10    double-blind, multicentre, parallel, prospecti...   \n",
       "16                                    open, prospective   \n",
       "478    crossover, double-blind, prospective, randomised   \n",
       "481                      multicentre, open, prospective   \n",
       "489            multicentre, open, parallel, prospective   \n",
       "570            multicentre, open, parallel, prospective   \n",
       "915                                   open, prospective   \n",
       "1507                     multicentre, open, prospective   \n",
       "1760                                        prospective   \n",
       "1812                                        prospective   \n",
       "1814                                        prospective   \n",
       "3880                                        prospective   \n",
       "\n",
       "                                        Trial Endpoints      ...       \\\n",
       "1     Incidence of adverse events\\ntime_frame: Up to...      ...        \n",
       "10    Progression-free survival (PFS) per RECIST 1.1...      ...        \n",
       "16    Maximum observed plasma concentration (Cmax) o...      ...        \n",
       "478   Placebo-corrected change-from-baseline in QTcF...      ...        \n",
       "481   Incidence and severity of adverse events\\nsafe...      ...        \n",
       "489   Maximum observed concentration\\ndescription: P...      ...        \n",
       "570   Area under the concentration-time curve (AUC) ...      ...        \n",
       "915   Area under the concentration-time curve (AUC) ...      ...        \n",
       "1507  Characterize the safety profile of the study d...      ...        \n",
       "1760                                                NaN      ...        \n",
       "1812                                                NaN      ...        \n",
       "1814                                                NaN      ...        \n",
       "3880                                                NaN      ...        \n",
       "\n",
       "             Trial End date                  Trial Status  \\\n",
       "1     01 Jul 2019 (planned)  Active, no longer recruiting   \n",
       "10    01 Jul 2021 (planned)                    Recruiting   \n",
       "16    01 Mar 2019 (planned)                    Recruiting   \n",
       "478   01 Mar 2019 (planned)                    Recruiting   \n",
       "481   01 Jul 2019 (planned)  Active, no longer recruiting   \n",
       "489   01 May 2019 (planned)                    Recruiting   \n",
       "570    28 Dec 2018 (actual)                     Completed   \n",
       "915    30 Jan 2018 (actual)                     Completed   \n",
       "1507   01 Mar 2013 (actual)                     Completed   \n",
       "1760              (planned)                     Suspended   \n",
       "1812              (planned)                      Planning   \n",
       "1814              (planned)                      Planning   \n",
       "3880              (planned)                      Planning   \n",
       "\n",
       "                                          Trial History  \\\n",
       "1     2019-03-06|Other trial event|Last checked agai...   \n",
       "10    2019-03-06|Other trial event|Last checked agai...   \n",
       "16    2019-03-06|Other trial event|Last checked agai...   \n",
       "478   2019-02-03|Other trial event|Last checked agai...   \n",
       "481   2019-02-01|Other trial event|Last checked agai...   \n",
       "489   2019-02-01|Other trial event|Last checked agai...   \n",
       "570   2019-01-22|Other trial event|Last checked agai...   \n",
       "915        2018-12-05|New trial record|New trial record   \n",
       "1507  2018-08-31|Biomarker Update|Biomarkers informa...   \n",
       "1760  2018-04-05|Other trial event|Last checked agai...   \n",
       "1812  2018-03-09|Other trial event|According to a Se...   \n",
       "1814  2018-03-09|Other trial event|According to a Se...   \n",
       "3880       2013-08-09|New trial record|New trial record   \n",
       "\n",
       "                                       Diseases treated Biomarkers-Inclusion  \\\n",
       "1     Advanced breast cancer|treatment|second-line o...                 HER2   \n",
       "10    Advanced breast cancer|treatment|second-line o...                 HER2   \n",
       "16    Breast cancer|treatment|; Colorectal cancer|tr...                  NaN   \n",
       "478   Breast cancer|treatment|; Colorectal cancer|tr...                  NaN   \n",
       "481   Advanced breast cancer|treatment|stage IV; Mal...                 HER2   \n",
       "489   Breast cancer|treatment|; Colorectal cancer|tr...                  NaN   \n",
       "570   Breast cancer|treatment|; Colorectal cancer|tr...                  NaN   \n",
       "915   Breast cancer|treatment|; Colorectal cancer|tr...                  NaN   \n",
       "1507  Advanced breast cancer|treatment|second-line o...                 HER2   \n",
       "1760  Breast cancer|treatment|second-line or greater...                  NaN   \n",
       "1812                   Breast cancer|treatment|stage IV                  NaN   \n",
       "1814                           Breast cancer|treatment|                  NaN   \n",
       "3880  Advanced breast cancer|treatment|; Brain metas...                  NaN   \n",
       "\n",
       "     Biomarkers-Exclusion  Biomarkers-Outcome Measure Biomarkers-Safety  \\\n",
       "1                    HER2                         NaN               NaN   \n",
       "10                   HER2                         NaN               NaN   \n",
       "16                    NaN                         NaN               NaN   \n",
       "478                   NaN                         NaN               NaN   \n",
       "481                  HER2                         NaN               NaN   \n",
       "489                   NaN                         NaN               NaN   \n",
       "570                   NaN                         NaN               NaN   \n",
       "915                   NaN                         NaN               NaN   \n",
       "1507                  NaN                        HER2               NaN   \n",
       "1760                  NaN                         NaN               NaN   \n",
       "1812                  NaN                         NaN               NaN   \n",
       "1814                  NaN                         NaN               NaN   \n",
       "3880                  NaN                         NaN               NaN   \n",
       "\n",
       "      Biomarkers-not specified Primary Drugs  \n",
       "1                          NaN     Tucatinib  \n",
       "10                         NaN     Tucatinib  \n",
       "16                         NaN     Tucatinib  \n",
       "478                        NaN     Tucatinib  \n",
       "481                        NaN     Tucatinib  \n",
       "489                        NaN     Tucatinib  \n",
       "570                        NaN     Tucatinib  \n",
       "915                        NaN     Tucatinib  \n",
       "1507                       NaN     Tucatinib  \n",
       "1760                       NaN     Tucatinib  \n",
       "1812                       NaN     Tucatinib  \n",
       "1814                       NaN     Tucatinib  \n",
       "3880                       NaN     Tucatinib  \n",
       "\n",
       "[13 rows x 41 columns]"
      ]
     },
     "execution_count": 79,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials[trials['Primary Drugs']=='Tucatinib']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-11T18:49:46.532099Z",
     "start_time": "2019-03-11T18:49:46.491868Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Date</th>\n",
       "      <th>Status</th>\n",
       "      <th>Notes</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2019-03-06</td>\n",
       "      <td>Other trial event</td>\n",
       "      <td>Last checked against ClinicalTrials.gov record.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2019-01-25</td>\n",
       "      <td>Other trial event</td>\n",
       "      <td>Last checked against the European Clinical Tri...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2018-12-26</td>\n",
       "      <td>Other trial event</td>\n",
       "      <td>New source identified and integrated (European...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2018-12-19</td>\n",
       "      <td>Status change - recruiting</td>\n",
       "      <td>Status changed from not yet recruiting to recr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2018-11-06</td>\n",
       "      <td>New trial record</td>\n",
       "      <td>New trial record</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "          Date                      Status  \\\n",
       "0   2019-03-06           Other trial event   \n",
       "1   2019-01-25           Other trial event   \n",
       "2   2018-12-26           Other trial event   \n",
       "3   2018-12-19  Status change - recruiting   \n",
       "4   2018-11-06            New trial record   \n",
       "\n",
       "                                               Notes  \n",
       "0    Last checked against ClinicalTrials.gov record.  \n",
       "1  Last checked against the European Clinical Tri...  \n",
       "2  New source identified and integrated (European...  \n",
       "3  Status changed from not yet recruiting to recr...  \n",
       "4                                   New trial record  "
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def trial_history_to_table(th):\n",
    "    rows = str.split(th, ';')\n",
    "    #columns_trial_1 = [str.split(i, '|') for i in rows_trial_1]\n",
    "    table = [str.split(row, '|') for row in rows]\n",
    "    return pd.DataFrame(table,columns=['Date','Status','Notes'])\n",
    "\n",
    "trial_history_to_table(phase_three['Trial History'].values[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-11T18:31:25.238293Z",
     "start_time": "2019-03-11T18:31:25.198597Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>a</th>\n",
       "      <th>b</th>\n",
       "      <th>c</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>4</td>\n",
       "      <td>5</td>\n",
       "      <td>6</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   a  b  c\n",
       "0  1  2  3\n",
       "1  4  5  6"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.DataFrame([[1,2,3],[4,5,6]],columns=['a','b','c'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-07T19:51:15.427039Z",
     "start_time": "2019-03-07T19:51:15.381839Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Trial ID</th>\n",
       "      <th>Trial Title</th>\n",
       "      <th>Mechanism of action</th>\n",
       "      <th>Drug class (therapeutic effect)</th>\n",
       "      <th>Drug class (chemical)</th>\n",
       "      <th>Drug class (biological)</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Organisations</th>\n",
       "      <th>Trial Design</th>\n",
       "      <th>Trial Endpoints</th>\n",
       "      <th>...</th>\n",
       "      <th>Trial Status</th>\n",
       "      <th>Trial History</th>\n",
       "      <th>Diseases treated</th>\n",
       "      <th>Biomarkers-Inclusion</th>\n",
       "      <th>Biomarkers-Exclusion</th>\n",
       "      <th>Biomarkers-Outcome Measure</th>\n",
       "      <th>Biomarkers-Safety</th>\n",
       "      <th>Biomarkers-not specified</th>\n",
       "      <th>Primary Drugs</th>\n",
       "      <th>split_end_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>700301099</td>\n",
       "      <td>A Phase 1/1b Study to Evaluate the Safety and ...</td>\n",
       "      <td>Adenosine A2A receptor antagonists, Adenosine ...</td>\n",
       "      <td>Antineoplastics, Antineoplastics, Antivirals, ...</td>\n",
       "      <td>Small molecules, Anthracyclines, Doxorubicins,...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Advanced breast cancer, Ovarian cancer</td>\n",
       "      <td>Arcus Biosciences, Arcus Biosciences</td>\n",
       "      <td>multicentre, open, prospective, sequential</td>\n",
       "      <td>Number of Participants with Treatment Emergent...</td>\n",
       "      <td>...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Advanced breast cancer|treatment|second-line o...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AB-928</td>\n",
       "      <td>[30, Jul, 2021, (planned)]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>700240183</td>\n",
       "      <td>A Phase 1b, Open-label Study to Assess the Saf...</td>\n",
       "      <td>Antibody-dependent cell cytotoxicity, Antimeta...</td>\n",
       "      <td>Antineoplastics, Antineoplastics, Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>Monoclonal antibodies</td>\n",
       "      <td>Advanced breast cancer, Male breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>multicentre, open, parallel, prospective</td>\n",
       "      <td>Incidence of adverse events\\ntime_frame: Up to...</td>\n",
       "      <td>...</td>\n",
       "      <td>Active, no longer recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Advanced breast cancer|treatment|second-line o...</td>\n",
       "      <td>HER2</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "      <td>[01, Jul, 2019, (planned)]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>700303393</td>\n",
       "      <td>A Multicenter, Open-label Phase 2 Study of Len...</td>\n",
       "      <td>Platelet derived growth factor alpha receptor ...</td>\n",
       "      <td>Antineoplastics, Immunotherapies, Antineoplastics</td>\n",
       "      <td>Amides, Chlorobenzenes, Cyclopropanes, Phenyl ...</td>\n",
       "      <td>Monoclonal antibodies</td>\n",
       "      <td>Biliary cancer, Breast cancer, Colorectal canc...</td>\n",
       "      <td>Eisai Inc, Merck Sharp &amp; Dohme, Merck Sharp &amp; ...</td>\n",
       "      <td>multicentre, open, prospective</td>\n",
       "      <td>Objective Response Rate (ORR) per Response Eva...</td>\n",
       "      <td>...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Biliary cancer|treatment|; Breast cancer|treat...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Lenvatinib, Pembrolizumab</td>\n",
       "      <td>[11, Apr, 2022, (planned)]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>700227141</td>\n",
       "      <td>Cohort Study of Prospective Validation of Pred...</td>\n",
       "      <td>Angiogenesis inhibitors, Angiogenesis inhibito...</td>\n",
       "      <td>Antineoplastics, Eye disorder therapies, Antin...</td>\n",
       "      <td>Diterpenes, Paclitaxels, Small molecules, Taxanes</td>\n",
       "      <td>Monoclonal antibodies</td>\n",
       "      <td>Adenocarcinoma, Advanced breast cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cohort, multicentre, observational, prospective</td>\n",
       "      <td>Measure of the initial rates and changes in CE...</td>\n",
       "      <td>...</td>\n",
       "      <td>Active, no longer recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Adenocarcinoma|treatment|first-line therapy, s...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Bevacizumab, Paclitaxel</td>\n",
       "      <td>[01, Dec, 2020, (planned)]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>700243825</td>\n",
       "      <td>A Phase Ib/II Randomized Study of BI 836845 in...</td>\n",
       "      <td>Aromatase inhibitors, B cell inhibitors, Estro...</td>\n",
       "      <td>Antineoplastics, Antineoplastics, Antineoplastics</td>\n",
       "      <td>Androstadienes, Small molecules, Macrolides, P...</td>\n",
       "      <td>Monoclonal antibodies</td>\n",
       "      <td>Advanced breast cancer</td>\n",
       "      <td>Boehringer Ingelheim, Boehringer Ingelheim</td>\n",
       "      <td>multicentre, open, parallel, prospective, rand...</td>\n",
       "      <td>Progression-free survival (PFS)\\n[ Time Frame:...</td>\n",
       "      <td>...</td>\n",
       "      <td>Active, no longer recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Advanced breast cancer|treatment|second-line o...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>A1C, ER alpha, HER2, PGR</td>\n",
       "      <td>Xentuzumab</td>\n",
       "      <td>[12, Nov, 2019, (planned)]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows  42 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    Trial ID                                        Trial Title  \\\n",
       "0  700301099  A Phase 1/1b Study to Evaluate the Safety and ...   \n",
       "1  700240183  A Phase 1b, Open-label Study to Assess the Saf...   \n",
       "2  700303393  A Multicenter, Open-label Phase 2 Study of Len...   \n",
       "3  700227141  Cohort Study of Prospective Validation of Pred...   \n",
       "4  700243825  A Phase Ib/II Randomized Study of BI 836845 in...   \n",
       "\n",
       "                                 Mechanism of action  \\\n",
       "0  Adenosine A2A receptor antagonists, Adenosine ...   \n",
       "1  Antibody-dependent cell cytotoxicity, Antimeta...   \n",
       "2  Platelet derived growth factor alpha receptor ...   \n",
       "3  Angiogenesis inhibitors, Angiogenesis inhibito...   \n",
       "4  Aromatase inhibitors, B cell inhibitors, Estro...   \n",
       "\n",
       "                     Drug class (therapeutic effect)  \\\n",
       "0  Antineoplastics, Antineoplastics, Antivirals, ...   \n",
       "1  Antineoplastics, Antineoplastics, Antineoplastics   \n",
       "2  Antineoplastics, Immunotherapies, Antineoplastics   \n",
       "3  Antineoplastics, Eye disorder therapies, Antin...   \n",
       "4  Antineoplastics, Antineoplastics, Antineoplastics   \n",
       "\n",
       "                               Drug class (chemical) Drug class (biological)  \\\n",
       "0  Small molecules, Anthracyclines, Doxorubicins,...                     NaN   \n",
       "1  2 ring heterocyclic compounds, Diamines, Furan...   Monoclonal antibodies   \n",
       "2  Amides, Chlorobenzenes, Cyclopropanes, Phenyl ...   Monoclonal antibodies   \n",
       "3  Diterpenes, Paclitaxels, Small molecules, Taxanes   Monoclonal antibodies   \n",
       "4  Androstadienes, Small molecules, Macrolides, P...   Monoclonal antibodies   \n",
       "\n",
       "                                          Indication  \\\n",
       "0             Advanced breast cancer, Ovarian cancer   \n",
       "1         Advanced breast cancer, Male breast cancer   \n",
       "2  Biliary cancer, Breast cancer, Colorectal canc...   \n",
       "3             Adenocarcinoma, Advanced breast cancer   \n",
       "4                             Advanced breast cancer   \n",
       "\n",
       "                                       Organisations  \\\n",
       "0               Arcus Biosciences, Arcus Biosciences   \n",
       "1  Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "2  Eisai Inc, Merck Sharp & Dohme, Merck Sharp & ...   \n",
       "3                                                NaN   \n",
       "4         Boehringer Ingelheim, Boehringer Ingelheim   \n",
       "\n",
       "                                        Trial Design  \\\n",
       "0         multicentre, open, prospective, sequential   \n",
       "1           multicentre, open, parallel, prospective   \n",
       "2                     multicentre, open, prospective   \n",
       "3    cohort, multicentre, observational, prospective   \n",
       "4  multicentre, open, parallel, prospective, rand...   \n",
       "\n",
       "                                     Trial Endpoints  \\\n",
       "0  Number of Participants with Treatment Emergent...   \n",
       "1  Incidence of adverse events\\ntime_frame: Up to...   \n",
       "2  Objective Response Rate (ORR) per Response Eva...   \n",
       "3  Measure of the initial rates and changes in CE...   \n",
       "4  Progression-free survival (PFS)\\n[ Time Frame:...   \n",
       "\n",
       "              ...                              Trial Status  \\\n",
       "0             ...                                Recruiting   \n",
       "1             ...              Active, no longer recruiting   \n",
       "2             ...                                Recruiting   \n",
       "3             ...              Active, no longer recruiting   \n",
       "4             ...              Active, no longer recruiting   \n",
       "\n",
       "                                       Trial History  \\\n",
       "0  2019-03-06|Other trial event|Last checked agai...   \n",
       "1  2019-03-06|Other trial event|Last checked agai...   \n",
       "2  2019-03-06|Other trial event|Last checked agai...   \n",
       "3  2019-03-06|Other trial event|Last checked agai...   \n",
       "4  2019-03-06|Other trial event|Last checked agai...   \n",
       "\n",
       "                                    Diseases treated Biomarkers-Inclusion  \\\n",
       "0  Advanced breast cancer|treatment|second-line o...                  NaN   \n",
       "1  Advanced breast cancer|treatment|second-line o...                 HER2   \n",
       "2  Biliary cancer|treatment|; Breast cancer|treat...                  NaN   \n",
       "3  Adenocarcinoma|treatment|first-line therapy, s...                  NaN   \n",
       "4  Advanced breast cancer|treatment|second-line o...                  NaN   \n",
       "\n",
       "  Biomarkers-Exclusion Biomarkers-Outcome Measure  Biomarkers-Safety  \\\n",
       "0                  NaN                        NaN                NaN   \n",
       "1                 HER2                        NaN                NaN   \n",
       "2                  NaN                        NaN                NaN   \n",
       "3                  NaN                        NaN                NaN   \n",
       "4                  NaN                        NaN                NaN   \n",
       "\n",
       "   Biomarkers-not specified              Primary Drugs  \\\n",
       "0                       NaN                     AB-928   \n",
       "1                       NaN                  Tucatinib   \n",
       "2                       NaN  Lenvatinib, Pembrolizumab   \n",
       "3                       NaN    Bevacizumab, Paclitaxel   \n",
       "4  A1C, ER alpha, HER2, PGR                 Xentuzumab   \n",
       "\n",
       "               split_end_date  \n",
       "0  [30, Jul, 2021, (planned)]  \n",
       "1  [01, Jul, 2019, (planned)]  \n",
       "2  [11, Apr, 2022, (planned)]  \n",
       "3  [01, Dec, 2020, (planned)]  \n",
       "4  [12, Nov, 2019, (planned)]  \n",
       "\n",
       "[5 rows x 42 columns]"
      ]
     },
     "execution_count": 67,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-07T17:50:32.705511Z",
     "start_time": "2019-03-07T17:50:32.678697Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0               Advanced breast cancer, Ovarian cancer\n",
       "1           Advanced breast cancer, Male breast cancer\n",
       "2    Biliary cancer, Breast cancer, Colorectal canc...\n",
       "3               Adenocarcinoma, Advanced breast cancer\n",
       "4                               Advanced breast cancer\n",
       "5                  Adenocarcinoma, Early breast cancer\n",
       "6    Advanced breast cancer, Non-Hodgkin's lymphoma...\n",
       "7    Advanced breast cancer, Cervical cancer, Endom...\n",
       "8               Adenocarcinoma, Advanced breast cancer\n",
       "9                    Breast cancer, Male breast cancer\n",
       "Name: Indication, dtype: object"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials['Indication'].head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-07T17:50:35.930786Z",
     "start_time": "2019-03-07T17:50:35.922817Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['Trial ID', 'Trial Title', 'Mechanism of action',\n",
       "       'Drug class (therapeutic effect)', 'Drug class (chemical)',\n",
       "       'Drug class (biological)', 'Indication', 'Organisations',\n",
       "       'Trial Design', 'Trial Endpoints', 'Primary Endpoints', 'Location',\n",
       "       'Phase of Trial', 'Subject Age', 'Patient Exclusion Criteria',\n",
       "       'Patient Inclusion Criteria', 'Subject Number', 'Subject Type',\n",
       "       'Planned Subject Number', 'Trial Acronym(s)', 'Trial Identifier',\n",
       "       'Drug Details', 'Trial Results', 'Trial Results - efficacy',\n",
       "       'Trial Results - tolerability', 'Trial  Results - other',\n",
       "       'Trial Centre Details', 'Lead Centre', 'Investigators',\n",
       "       'Trial Comments', 'Trial Initiation date', 'Trial End date',\n",
       "       'Trial Status', 'Trial History', 'Diseases treated',\n",
       "       'Biomarkers-Inclusion', 'Biomarkers-Exclusion',\n",
       "       'Biomarkers-Outcome Measure', 'Biomarkers-Safety',\n",
       "       'Biomarkers-not specified', 'Primary Drugs'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 161,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-09T03:21:10.552846Z",
     "start_time": "2019-03-09T03:21:10.540442Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0        15 Oct 2018 (actual)\n",
       "1        01 Dec 2013 (actual)\n",
       "2        12 Feb 2019 (actual)\n",
       "3        01 Jun 2012 (actual)\n",
       "4        15 May 2014 (actual)\n",
       "5        27 Dec 2018 (actual)\n",
       "6        16 Mar 2011 (actual)\n",
       "7        12 Aug 2015 (actual)\n",
       "8        22 Mar 2017 (actual)\n",
       "9        22 Aug 2018 (actual)\n",
       "10       01 Dec 2015 (actual)\n",
       "11       05 Feb 2015 (actual)\n",
       "12       13 Jan 2017 (actual)\n",
       "13      01 Mar 2019 (planned)\n",
       "14      28 Mar 2019 (planned)\n",
       "15       15 Nov 2016 (actual)\n",
       "16       12 Feb 2019 (actual)\n",
       "17       01 Mar 2015 (actual)\n",
       "18       05 Feb 2019 (actual)\n",
       "19       01 Dec 2007 (actual)\n",
       "20       22 Jun 2010 (actual)\n",
       "21       01 Dec 2005 (actual)\n",
       "22       16 Oct 2008 (actual)\n",
       "23       20 Jun 2018 (actual)\n",
       "24       24 Aug 2011 (actual)\n",
       "25       06 Dec 2016 (actual)\n",
       "26       17 Jan 2012 (actual)\n",
       "27       01 Jul 2015 (actual)\n",
       "28       01 Jan 2014 (actual)\n",
       "29       14 Aug 2017 (actual)\n",
       "                ...          \n",
       "4499                (planned)\n",
       "4500                (planned)\n",
       "4501     24 Sep 2004 (actual)\n",
       "4502     29 Nov 2004 (actual)\n",
       "4503                (planned)\n",
       "4504                (planned)\n",
       "4505                (planned)\n",
       "4506     01 Oct 1990 (actual)\n",
       "4507     01 Sep 2005 (actual)\n",
       "4508                (planned)\n",
       "4509                (planned)\n",
       "4510     01 Aug 2002 (actual)\n",
       "4511     01 Aug 2003 (actual)\n",
       "4512     01 Feb 2000 (actual)\n",
       "4513     01 Nov 1994 (actual)\n",
       "4514                (planned)\n",
       "4515     01 Mar 1999 (actual)\n",
       "4516     01 Jun 1998 (actual)\n",
       "4517     01 Dec 1997 (actual)\n",
       "4518     01 May 2003 (actual)\n",
       "4519     01 Jun 2000 (actual)\n",
       "4520     01 Oct 1998 (actual)\n",
       "4521     01 Aug 2000 (actual)\n",
       "4522     01 Oct 1997 (actual)\n",
       "4523     01 Jun 1997 (actual)\n",
       "4524     01 Jul 2000 (actual)\n",
       "4525     01 Feb 1997 (actual)\n",
       "4526     06 Jun 2003 (actual)\n",
       "4527     01 Jun 1999 (actual)\n",
       "4528     01 Oct 2004 (actual)\n",
       "Name: Trial Initiation date, Length: 4529, dtype: object"
      ]
     },
     "execution_count": 161,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials['Trial Initiation date']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-07T19:52:58.381975Z",
     "start_time": "2019-03-07T19:52:58.368140Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Lenvatinib|Oral|Capsule; Pembrolizumab|Intravenous|Infusion',\n",
       "       'Bevacizumab|Intravenous|Infusion; Paclitaxel||',\n",
       "       'Everolimus|Oral|Tablet; Exemestane|Oral|; Xentuzumab|Intravenous|Infusion'],\n",
       "      dtype=object)"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials['Drug Details'].values[2:5] #drug, method of use, trials"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-07T20:01:44.783305Z",
     "start_time": "2019-03-07T20:01:44.776078Z"
    }
   },
   "outputs": [],
   "source": [
    "#str.split(trials['Trial History'].values[1], ';')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 154,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-09T03:17:07.417950Z",
     "start_time": "2019-03-09T03:17:07.365677Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['2019-03-06|Other trial event|Last checked against ClinicalTrials.gov record.',\n",
       " ' 2018-08-31|Completion date|Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.',\n",
       " ' 2018-08-31|Other trial event|Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.',\n",
       " ' 2018-08-31|Biomarker Update|Biomarkers information updated',\n",
       " ' 2018-06-05|Results|Results of an retrospective pooled analysis (NCT01983501 and NCT02025192) assessing clinical benefit of tucatinib after isolated brain progression presented at the 54th Annual Meeting of the American Society of Clinical Oncology',\n",
       " ' 2018-05-24|Results|Results assessing the safety, tolerabilty, pharmacokinetics and recommended phase 2 dose published in the Lancet Oncology',\n",
       " ' 2018-03-09|Other trial event|According to a Seattle Genetics media release, Cascadian Therapeutics has been acquired by Seattle Genetics, and this acquisition provides the Global Rights of Tucatinib to Seattle Genetics.',\n",
       " ' 2018-01-04|Other trial event|According to a Cascadian Therapeutics media release, data will be published in peer-reviewed journals during 2018',\n",
       " ' 2018-01-04|Results|According to a Cascadian Therapeutics media release, in december results were presented at the 2017 San Antonio Breast Cancer Symposium (SABCS).',\n",
       " ' 2017-12-09|Results|Results of a pooled analysis from ONT-380-005/Triplet and ONT-380-004 studies (n = 77), presented at the 40th Annual San Antonio Breast Cancer Symposium',\n",
       " ' 2017-12-07|Results|Pooled results of the ONT-380-005/Triplet and ONT-380-004 studies (n = 77) presented in a Cascadian Therapeutics media release.',\n",
       " ' 2017-12-07|Other trial event|According to a Cascadian Therapeutics media release, pooled analysis of data from the ONT-380-005/Triplet study and ONT-380-004 studies (n = 77) will be presented at the 2017 San Antonio Breast Cancer Symposium (SABCS).',\n",
       " ' 2017-09-12|Results|Results presented at the 42nd European Society for Medical Oncology Congress',\n",
       " ' 2017-09-12|Results|Results of a pooled analysis comparing PFS and the site of relapse in patients with or without brain metastases from two phase I trials (ONT-380-004 and ONT-380-005',\n",
       " ' n=77) presented at the 42nd European Society for Medical Oncology Congress',\n",
       " ' 2017-08-10|Completion date|Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.',\n",
       " ' 2017-08-10|Other trial event|Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.',\n",
       " ' 2017-01-05|Results|Updated results presented at the 2016 San Antonio Breast Cancer Symposium (SABCS), according to a Cascadian Therapeutics media release.',\n",
       " ' 2016-12-10|Results|Results of interim analysis (n=27) presented at the 39th Annual San Antonio Breast Cancer Symposium',\n",
       " ' 2016-12-07|Results|Results published in the Cascadian Therapeutics Media Release.',\n",
       " ' 2016-11-07|Interim results|Interim data of eight patients from this trial presented at ESMO 2016, as reported by a Cascadian Therapeutics media release.',\n",
       " ' 2016-10-11|Results|Results assessing Cutaneous responses presented at the 41st European Society for Medical Oncology Congress.',\n",
       " ' 2016-10-10|Other trial event|According to a Cascadian Therapeutics media release, the company will present updated data from this trial at the San Antonion Breast Cancer Symposium in December 2016.',\n",
       " ' 2016-10-10|Results|Results published in the Cascadian Therapeutics Media Release.',\n",
       " ' 2016-10-04|Other trial event|According to a Cascadian Therapeutics media release, the company plans to present updated data from this trial at the San Antonion Breast Cancer Symposium in December 2016.',\n",
       " ' 2016-09-28|Other trial event|According to a Cascadian Therapeutics media release, data from the study will be presented at the European Society of Medical Oncology (ESMO) 2016 Congress.',\n",
       " ' 2016-08-08|Other trial event|According to Cascadian Therapeutics media release, the comapny expects to present more mature data from the Triplet study before the end of the year.',\n",
       " ' 2016-07-21|Completion date|Planned End Date changed from 1 Jun 2016 to 1 Jul 2017.',\n",
       " ' 2016-07-21|Other trial event|Planned primary completion date changed from 1 May 2016 to 1 Jul 2017.',\n",
       " ' 2016-06-14|Results|Results published in a Cascadian Therapeutics media release.',\n",
       " \" 2016-06-05|Other trial event|According to an Oncothyreon media release updated data from this study will be presented at the Company's R&D Day on June 14th 2016 in New York City.\",\n",
       " ' 2016-01-25|Status change - active, no longer recruiting|Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.',\n",
       " ' 2015-12-12|Results|Pooled results of 24 patients from 2 trials including this study and another study [see CTP 700238859] were presented at the 38th Annual San Antonio Breast Cancer Symposium.',\n",
       " ' 2015-12-07|Other trial event|Results will be presented at the San Antonio Breast Cancer Symposium (SABCS), as per Oncothyreon media release.',\n",
       " ' 2015-11-09|Results|Results of pooled analysis of two trials (NCT02025192 and NCT02614794) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015',\n",
       " ' 2015-06-02|Results|Pooled analysis',\n",
       " ' efficacy in CNS mets (NCT01983501, NCT02025192) results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.',\n",
       " ' 2015-06-02|Interim results|Interim results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.',\n",
       " ' 2015-05-30|Other trial event|According to an Oncothyreon media release, data from his trial were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.',\n",
       " ' 2015-05-30|Other trial event|According to a Oncothyreon media release, data from this trial support to start phase II trial of Irbinitinib (ONT-380) in HER2+ metastatic breast cancer indication (see trial 700257487).',\n",
       " ' 2015-05-28|Other trial event|Planned number of patients changed from 138 to 153, according to ClinicalTrials.gov record.',\n",
       " ' 2014-12-12|Interim results|Interim results presented at the 37th Annual San Antonio Breast Cancer Symposium.',\n",
       " ' 2014-12-12|Interim results|Interim results published in an Oncothyreon media release.',\n",
       " ' 2014-12-12|Other trial event|According to an Oncothyreon media release, positive preliminary data from this trial will be presented at the San Antonio Breast Cancer Symposium.',\n",
       " ' 2014-10-16|Other trial event|Last checked against M.D. Anderson Cancer Center record.',\n",
       " ' 2014-06-26|Other trial event|New source identified and integrated (M.D. Anderson Cancer Center -2014-0013).',\n",
       " ' 2014-01-08|New trial record|New trial record']"
      ]
     },
     "execution_count": 154,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "rows_trial_1 = str.split(trials['Trial History'].values[1], ';')\n",
    "#columns_trial_1 = [str.split(i, '|') for i in rows_trial_1]\n",
    "columns_trial_1 = str.split(rows_trial_1[0], '|')\n",
    "rows_trial_1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-07T18:01:21.045523Z",
     "start_time": "2019-03-07T18:01:21.040446Z"
    }
   },
   "outputs": [],
   "source": [
    "# one_split = trials['split_end_date'].values[0]\n",
    "# pd.to_datetime(' '.join(one_split[:3]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 162,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-09T03:22:42.839853Z",
     "start_time": "2019-03-09T03:22:42.371427Z"
    }
   },
   "outputs": [],
   "source": [
    "trials['split_start_date'] = trials['Trial Initiation date'].apply(lambda x: x.split(' '))\n",
    "\n",
    "trials['split_end_date'] = trials['Trial End date'].apply(lambda x: x.split(' '))\n",
    "in_progress_trials = trials[trials['split_start_date'].apply(lambda x: len(x[:3]))==3]\n",
    "planned_trials = trials[trials['split_start_date'].apply(lambda x: len(x[:3]))==2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-08T16:26:56.105182Z",
     "start_time": "2019-03-08T16:26:56.097769Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 111,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "planned_trials.shape[0]+in_progress_trials.shape[0]==trials.shape[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 157,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-09T03:19:40.421328Z",
     "start_time": "2019-03-09T03:19:40.385544Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Trial ID</th>\n",
       "      <th>Trial Title</th>\n",
       "      <th>Mechanism of action</th>\n",
       "      <th>Drug class (therapeutic effect)</th>\n",
       "      <th>Drug class (chemical)</th>\n",
       "      <th>Drug class (biological)</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Organisations</th>\n",
       "      <th>Trial Design</th>\n",
       "      <th>Trial Endpoints</th>\n",
       "      <th>...</th>\n",
       "      <th>Trial Status</th>\n",
       "      <th>Trial History</th>\n",
       "      <th>Diseases treated</th>\n",
       "      <th>Biomarkers-Inclusion</th>\n",
       "      <th>Biomarkers-Exclusion</th>\n",
       "      <th>Biomarkers-Outcome Measure</th>\n",
       "      <th>Biomarkers-Safety</th>\n",
       "      <th>Biomarkers-not specified</th>\n",
       "      <th>Primary Drugs</th>\n",
       "      <th>split_end_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>700301099</td>\n",
       "      <td>A Phase 1/1b Study to Evaluate the Safety and ...</td>\n",
       "      <td>Adenosine A2A receptor antagonists, Adenosine ...</td>\n",
       "      <td>Antineoplastics, Antineoplastics, Antivirals, ...</td>\n",
       "      <td>Small molecules, Anthracyclines, Doxorubicins,...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Advanced breast cancer, Ovarian cancer</td>\n",
       "      <td>Arcus Biosciences, Arcus Biosciences</td>\n",
       "      <td>multicentre, open, prospective, sequential</td>\n",
       "      <td>Number of Participants with Treatment Emergent...</td>\n",
       "      <td>...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Advanced breast cancer|treatment|second-line o...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AB-928</td>\n",
       "      <td>[30, Jul, 2021, (planned)]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>700240183</td>\n",
       "      <td>A Phase 1b, Open-label Study to Assess the Saf...</td>\n",
       "      <td>Antibody-dependent cell cytotoxicity, Antimeta...</td>\n",
       "      <td>Antineoplastics, Antineoplastics, Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>Monoclonal antibodies</td>\n",
       "      <td>Advanced breast cancer, Male breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>multicentre, open, parallel, prospective</td>\n",
       "      <td>Incidence of adverse events\\ntime_frame: Up to...</td>\n",
       "      <td>...</td>\n",
       "      <td>Active, no longer recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Advanced breast cancer|treatment|second-line o...</td>\n",
       "      <td>HER2</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "      <td>[01, Jul, 2019, (planned)]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>700303393</td>\n",
       "      <td>A Multicenter, Open-label Phase 2 Study of Len...</td>\n",
       "      <td>Platelet derived growth factor alpha receptor ...</td>\n",
       "      <td>Antineoplastics, Immunotherapies, Antineoplastics</td>\n",
       "      <td>Amides, Chlorobenzenes, Cyclopropanes, Phenyl ...</td>\n",
       "      <td>Monoclonal antibodies</td>\n",
       "      <td>Biliary cancer, Breast cancer, Colorectal canc...</td>\n",
       "      <td>Eisai Inc, Merck Sharp &amp; Dohme, Merck Sharp &amp; ...</td>\n",
       "      <td>multicentre, open, prospective</td>\n",
       "      <td>Objective Response Rate (ORR) per Response Eva...</td>\n",
       "      <td>...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Biliary cancer|treatment|; Breast cancer|treat...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Lenvatinib, Pembrolizumab</td>\n",
       "      <td>[11, Apr, 2022, (planned)]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>700227141</td>\n",
       "      <td>Cohort Study of Prospective Validation of Pred...</td>\n",
       "      <td>Angiogenesis inhibitors, Angiogenesis inhibito...</td>\n",
       "      <td>Antineoplastics, Eye disorder therapies, Antin...</td>\n",
       "      <td>Diterpenes, Paclitaxels, Small molecules, Taxanes</td>\n",
       "      <td>Monoclonal antibodies</td>\n",
       "      <td>Adenocarcinoma, Advanced breast cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cohort, multicentre, observational, prospective</td>\n",
       "      <td>Measure of the initial rates and changes in CE...</td>\n",
       "      <td>...</td>\n",
       "      <td>Active, no longer recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Adenocarcinoma|treatment|first-line therapy, s...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Bevacizumab, Paclitaxel</td>\n",
       "      <td>[01, Dec, 2020, (planned)]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>700243825</td>\n",
       "      <td>A Phase Ib/II Randomized Study of BI 836845 in...</td>\n",
       "      <td>Aromatase inhibitors, B cell inhibitors, Estro...</td>\n",
       "      <td>Antineoplastics, Antineoplastics, Antineoplastics</td>\n",
       "      <td>Androstadienes, Small molecules, Macrolides, P...</td>\n",
       "      <td>Monoclonal antibodies</td>\n",
       "      <td>Advanced breast cancer</td>\n",
       "      <td>Boehringer Ingelheim, Boehringer Ingelheim</td>\n",
       "      <td>multicentre, open, parallel, prospective, rand...</td>\n",
       "      <td>Progression-free survival (PFS)\\n[ Time Frame:...</td>\n",
       "      <td>...</td>\n",
       "      <td>Active, no longer recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Advanced breast cancer|treatment|second-line o...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>A1C, ER alpha, HER2, PGR</td>\n",
       "      <td>Xentuzumab</td>\n",
       "      <td>[12, Nov, 2019, (planned)]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows  42 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    Trial ID                                        Trial Title  \\\n",
       "0  700301099  A Phase 1/1b Study to Evaluate the Safety and ...   \n",
       "1  700240183  A Phase 1b, Open-label Study to Assess the Saf...   \n",
       "2  700303393  A Multicenter, Open-label Phase 2 Study of Len...   \n",
       "3  700227141  Cohort Study of Prospective Validation of Pred...   \n",
       "4  700243825  A Phase Ib/II Randomized Study of BI 836845 in...   \n",
       "\n",
       "                                 Mechanism of action  \\\n",
       "0  Adenosine A2A receptor antagonists, Adenosine ...   \n",
       "1  Antibody-dependent cell cytotoxicity, Antimeta...   \n",
       "2  Platelet derived growth factor alpha receptor ...   \n",
       "3  Angiogenesis inhibitors, Angiogenesis inhibito...   \n",
       "4  Aromatase inhibitors, B cell inhibitors, Estro...   \n",
       "\n",
       "                     Drug class (therapeutic effect)  \\\n",
       "0  Antineoplastics, Antineoplastics, Antivirals, ...   \n",
       "1  Antineoplastics, Antineoplastics, Antineoplastics   \n",
       "2  Antineoplastics, Immunotherapies, Antineoplastics   \n",
       "3  Antineoplastics, Eye disorder therapies, Antin...   \n",
       "4  Antineoplastics, Antineoplastics, Antineoplastics   \n",
       "\n",
       "                               Drug class (chemical) Drug class (biological)  \\\n",
       "0  Small molecules, Anthracyclines, Doxorubicins,...                     NaN   \n",
       "1  2 ring heterocyclic compounds, Diamines, Furan...   Monoclonal antibodies   \n",
       "2  Amides, Chlorobenzenes, Cyclopropanes, Phenyl ...   Monoclonal antibodies   \n",
       "3  Diterpenes, Paclitaxels, Small molecules, Taxanes   Monoclonal antibodies   \n",
       "4  Androstadienes, Small molecules, Macrolides, P...   Monoclonal antibodies   \n",
       "\n",
       "                                          Indication  \\\n",
       "0             Advanced breast cancer, Ovarian cancer   \n",
       "1         Advanced breast cancer, Male breast cancer   \n",
       "2  Biliary cancer, Breast cancer, Colorectal canc...   \n",
       "3             Adenocarcinoma, Advanced breast cancer   \n",
       "4                             Advanced breast cancer   \n",
       "\n",
       "                                       Organisations  \\\n",
       "0               Arcus Biosciences, Arcus Biosciences   \n",
       "1  Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "2  Eisai Inc, Merck Sharp & Dohme, Merck Sharp & ...   \n",
       "3                                                NaN   \n",
       "4         Boehringer Ingelheim, Boehringer Ingelheim   \n",
       "\n",
       "                                        Trial Design  \\\n",
       "0         multicentre, open, prospective, sequential   \n",
       "1           multicentre, open, parallel, prospective   \n",
       "2                     multicentre, open, prospective   \n",
       "3    cohort, multicentre, observational, prospective   \n",
       "4  multicentre, open, parallel, prospective, rand...   \n",
       "\n",
       "                                     Trial Endpoints  \\\n",
       "0  Number of Participants with Treatment Emergent...   \n",
       "1  Incidence of adverse events\\ntime_frame: Up to...   \n",
       "2  Objective Response Rate (ORR) per Response Eva...   \n",
       "3  Measure of the initial rates and changes in CE...   \n",
       "4  Progression-free survival (PFS)\\n[ Time Frame:...   \n",
       "\n",
       "              ...                              Trial Status  \\\n",
       "0             ...                                Recruiting   \n",
       "1             ...              Active, no longer recruiting   \n",
       "2             ...                                Recruiting   \n",
       "3             ...              Active, no longer recruiting   \n",
       "4             ...              Active, no longer recruiting   \n",
       "\n",
       "                                       Trial History  \\\n",
       "0  2019-03-06|Other trial event|Last checked agai...   \n",
       "1  2019-03-06|Other trial event|Last checked agai...   \n",
       "2  2019-03-06|Other trial event|Last checked agai...   \n",
       "3  2019-03-06|Other trial event|Last checked agai...   \n",
       "4  2019-03-06|Other trial event|Last checked agai...   \n",
       "\n",
       "                                    Diseases treated Biomarkers-Inclusion  \\\n",
       "0  Advanced breast cancer|treatment|second-line o...                  NaN   \n",
       "1  Advanced breast cancer|treatment|second-line o...                 HER2   \n",
       "2  Biliary cancer|treatment|; Breast cancer|treat...                  NaN   \n",
       "3  Adenocarcinoma|treatment|first-line therapy, s...                  NaN   \n",
       "4  Advanced breast cancer|treatment|second-line o...                  NaN   \n",
       "\n",
       "  Biomarkers-Exclusion Biomarkers-Outcome Measure  Biomarkers-Safety  \\\n",
       "0                  NaN                        NaN                NaN   \n",
       "1                 HER2                        NaN                NaN   \n",
       "2                  NaN                        NaN                NaN   \n",
       "3                  NaN                        NaN                NaN   \n",
       "4                  NaN                        NaN                NaN   \n",
       "\n",
       "   Biomarkers-not specified              Primary Drugs  \\\n",
       "0                       NaN                     AB-928   \n",
       "1                       NaN                  Tucatinib   \n",
       "2                       NaN  Lenvatinib, Pembrolizumab   \n",
       "3                       NaN    Bevacizumab, Paclitaxel   \n",
       "4  A1C, ER alpha, HER2, PGR                 Xentuzumab   \n",
       "\n",
       "               split_end_date  \n",
       "0  [30, Jul, 2021, (planned)]  \n",
       "1  [01, Jul, 2019, (planned)]  \n",
       "2  [11, Apr, 2022, (planned)]  \n",
       "3  [01, Dec, 2020, (planned)]  \n",
       "4  [12, Nov, 2019, (planned)]  \n",
       "\n",
       "[5 rows x 42 columns]"
      ]
     },
     "execution_count": 157,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "in_progress_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 152,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-08T20:09:57.029934Z",
     "start_time": "2019-03-08T20:09:56.992722Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'2019-03-06|Other trial event|Last checked against Clinicaltrials.gov record.; 2018-11-16|Results|Results presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 2018-10-23|Results|Results (n=59) from patients with PTEN-deficient cancers enrolled to Arms N and P treated with GSK2636771, presented at the 43rd European Society for Medical Oncology Congress.; 2018-09-24|Other trial event|According to a NeoGenomics media release, the company announced today that it is participating as a designated laboratory in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine cancer treatment clinical trial.; 2018-08-28|Other trial event|According to a OPKO Health media release, the BioReference Laboratories ( a subsidiary of OPKO Health ) has signed an agreement with NCI and ECOG-ACRIN to participate in this study.; 2018-08-02|Other trial event|According to a Tempus media release, the company (technology) is participating as a CLIA-certified/accredited laboratory for this trial. Under the terms of the collaboration, Tempus will reach out and notify treating oncologists from the more than 1,100 clinical sites participating in the trial when the Tempus xT assay identifies gene abnormalities that could make a patient eligible for one of several NCI-MATCH treatments.; 2018-06-26|New trial record|New trial record; 2018-06-05|Interim results|Results (arm W; n=50; as of June 2017) assessing the effect of AZD4547 in patients with tumors with aberrations in the FGFR pathway, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.'"
      ]
     },
     "execution_count": 152,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "planned_trials['Trial History'].values[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "drugs[drugs['Drug Name'].isin(trials['Primary Drugs'])]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-08T16:45:01.784709Z",
     "start_time": "2019-03-08T16:45:01.765074Z"
    }
   },
   "outputs": [],
   "source": [
    "basic_trials_series = trials['Phase of Trial'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 136,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-08T16:47:52.936634Z",
     "start_time": "2019-03-08T16:47:52.927801Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Phase II                  1837\n",
       "Phase I                   1036\n",
       "Phase III                  592\n",
       "Phase IV                   503\n",
       "Phase I/II                 452\n",
       "Phase II/III                41\n",
       "Phase 0                     35\n",
       "Clinical Phase Unknown      32\n",
       "Phase III/IV                 1\n",
       "Name: Phase of Trial, dtype: int64"
      ]
     },
     "execution_count": 136,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "basic_trials_series"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 134,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-08T16:46:23.199982Z",
     "start_time": "2019-03-08T16:46:23.181859Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "4529"
      ]
     },
     "execution_count": 134,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "basic_trials_series.sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-11T21:30:50.592135Z",
     "start_time": "2019-03-11T21:30:50.458565Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Roche, Roche                                                                                                              122\n",
       "Pfizer                                                                                                                     96\n",
       "AstraZeneca, AstraZeneca                                                                                                   93\n",
       "Novartis                                                                                                                   90\n",
       "Pfizer, Pfizer                                                                                                             80\n",
       "AstraZeneca                                                                                                                75\n",
       "Roche                                                                                                                      72\n",
       "Genentech                                                                                                                  58\n",
       "Novartis, Novartis                                                                                                         57\n",
       "GlaxoSmithKline, GlaxoSmithKline                                                                                           53\n",
       "GlaxoSmithKline                                                                                                            51\n",
       "Eli Lilly, Eli Lilly                                                                                                       40\n",
       "Bristol-Myers Squibb                                                                                                       39\n",
       "Merck Sharp & Dohme                                                                                                        35\n",
       "Amgen                                                                                                                      32\n",
       "Novartis Pharmaceuticals, Novartis Pharmaceuticals                                                                         29\n",
       "Sanofi                                                                                                                     28\n",
       "Bristol-Myers Squibb, Bristol-Myers Squibb                                                                                 28\n",
       "Genentech, Roche, Roche                                                                                                    26\n",
       "Eli Lilly                                                                                                                  24\n",
       "Genentech, Genentech                                                                                                       24\n",
       "Sanofi, Sanofi                                                                                                             20\n",
       "Celgene Corporation                                                                                                        19\n",
       "Genentech, Genentech, Roche                                                                                                17\n",
       "Eisai Inc                                                                                                                  17\n",
       "Eisai Co Ltd                                                                                                               17\n",
       "Novartis, Novartis, Novartis Pharmaceuticals, Novartis Pharmaceuticals                                                     15\n",
       "Amgen, Amgen                                                                                                               14\n",
       "Bayer, Bayer                                                                                                               14\n",
       "Pierre Fabre, Pierre Fabre                                                                                                 12\n",
       "                                                                                                                         ... \n",
       "Advanced Accelerator Applications                                                                                           1\n",
       "Dako A/S                                                                                                                    1\n",
       "Ligand Pharmaceuticals                                                                                                      1\n",
       "Boehringer Ingelheim, Boehringer Ingelheim, Boehringer Ingelheim Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals      1\n",
       "Bristol-Myers Squibb, Pfizer                                                                                                1\n",
       "CP Pharmaceuticals, Ebewe, Puma Biotechnology, Puma Biotechnology, Roche, Wyeth Pharmaceuticals, Wyeth Pharmaceuticals      1\n",
       "Zenus Pharma, Zenus Pharma                                                                                                  1\n",
       "Bristol-Myers Squibb, Bristol-Myers Squibb, GlaxoSmithKline                                                                 1\n",
       "Clovis Oncology, Pfizer                                                                                                     1\n",
       "Orion, Orion, Orion Pharma                                                                                                  1\n",
       "Thar Pharmaceuticals                                                                                                        1\n",
       "Arvinas                                                                                                                     1\n",
       "Cadila Pharmaceuticals, Cadila Pharmaceuticals, Oncology Venture                                                            1\n",
       "Pfizer, Pfizer, Puma Biotechnology                                                                                          1\n",
       "Chipscreen Biosciences, Chipscreen Biosciences                                                                              1\n",
       "Eli Lilly, Eli Lilly, Molecular Therapeutics                                                                                1\n",
       "Elea, Elea                                                                                                                  1\n",
       "Caris Life Sciences, Debiopharm, Debiopharm                                                                                 1\n",
       "Evelo Biosciences, Evelo Biosciences, Merck Sharp & Dohme                                                                   1\n",
       "GlaxoSmithKline, GlaxoSmithKline Research & Development, GlaxoSmithKline Research & Development, Novartis, Novartis         1\n",
       "Pevion Biotech                                                                                                              1\n",
       "SRI International, Taiho Pharmaceutical                                                                                     1\n",
       "Abraxis BioScience, Abraxis BioScience, American BioScience, American BioScience, Celgene Corporation                       1\n",
       "Celgene Corporation, Merck Sharp & Dohme                                                                                    1\n",
       "Aventis, Genentech                                                                                                          1\n",
       "Neurocrine Biosciences, Neurocrine Biosciences                                                                              1\n",
       "AnyGen, AnyGen                                                                                                              1\n",
       "IgDraSol, IgDraSol, Sorrento Therapeutics, Sorrento Therapeutics                                                            1\n",
       "Calithera Biosciences, Calithera Biosciences                                                                                1\n",
       "SciClone Pharmaceuticals                                                                                                    1\n",
       "Name: Organisations, Length: 1170, dtype: int64"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials['Organisations'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#total number of trials = 4529\n",
    "#total number that have been at phase 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-11T23:32:32.733055Z",
     "start_time": "2019-03-11T23:32:32.593424Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Trial ID</th>\n",
       "      <th>Trial Title</th>\n",
       "      <th>Mechanism of action</th>\n",
       "      <th>Drug class (therapeutic effect)</th>\n",
       "      <th>Drug class (chemical)</th>\n",
       "      <th>Drug class (biological)</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Organisations</th>\n",
       "      <th>Trial Design</th>\n",
       "      <th>Trial Endpoints</th>\n",
       "      <th>...</th>\n",
       "      <th>Trial End date</th>\n",
       "      <th>Trial Status</th>\n",
       "      <th>Trial History</th>\n",
       "      <th>Diseases treated</th>\n",
       "      <th>Biomarkers-Inclusion</th>\n",
       "      <th>Biomarkers-Exclusion</th>\n",
       "      <th>Biomarkers-Outcome Measure</th>\n",
       "      <th>Biomarkers-Safety</th>\n",
       "      <th>Biomarkers-not specified</th>\n",
       "      <th>Primary Drugs</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>700240183</td>\n",
       "      <td>A Phase 1b, Open-label Study to Assess the Saf...</td>\n",
       "      <td>Antibody-dependent cell cytotoxicity, Antimeta...</td>\n",
       "      <td>Antineoplastics, Antineoplastics, Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>Monoclonal antibodies</td>\n",
       "      <td>Advanced breast cancer, Male breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>multicentre, open, parallel, prospective</td>\n",
       "      <td>Incidence of adverse events\\ntime_frame: Up to...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Jul 2019 (planned)</td>\n",
       "      <td>Active, no longer recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Advanced breast cancer|treatment|second-line o...</td>\n",
       "      <td>HER2</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>700257487</td>\n",
       "      <td>Phase 2 Randomized, Double-Blinded, Controlled...</td>\n",
       "      <td>Antibody-dependent cell cytotoxicity, Antibody...</td>\n",
       "      <td>Antineoplastics, Antineoplastics, Antineoplast...</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>Monoclonal antibodies, Monoclonal antibodies</td>\n",
       "      <td>Advanced breast cancer, Carcinoma, Male breast...</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>double-blind, multicentre, parallel, prospecti...</td>\n",
       "      <td>Progression-free survival (PFS) per RECIST 1.1...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Jul 2021 (planned)</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Advanced breast cancer|treatment|second-line o...</td>\n",
       "      <td>HER2</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>700304216</td>\n",
       "      <td>A Phase 1, Open-Label, Fixed-Sequence, Drug-Dr...</td>\n",
       "      <td>AMP activated protein kinase stimulants, Emiss...</td>\n",
       "      <td>Antineoplastics, Antihyperglycaemics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer, Colorectal cancer</td>\n",
       "      <td>Seattle Genetics, Seattle Genetics</td>\n",
       "      <td>open, prospective</td>\n",
       "      <td>Maximum observed plasma concentration (Cmax) o...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Mar 2019 (planned)</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Breast cancer|treatment|; Colorectal cancer|tr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>478</th>\n",
       "      <td>700302859</td>\n",
       "      <td>A Phase 1, Randomized, Partially Double-Blind,...</td>\n",
       "      <td>DNA gyrase inhibitors, ERBB 2 receptor antagon...</td>\n",
       "      <td>Antineoplastics, Antibacterials</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer, Colorectal cancer</td>\n",
       "      <td>Seattle Genetics, Seattle Genetics</td>\n",
       "      <td>crossover, double-blind, prospective, randomised</td>\n",
       "      <td>Placebo-corrected change-from-baseline in QTcF...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Mar 2019 (planned)</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>2019-02-03|Other trial event|Last checked agai...</td>\n",
       "      <td>Breast cancer|treatment|; Colorectal cancer|tr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>481</th>\n",
       "      <td>700238859</td>\n",
       "      <td>A Phase 1b, Open-label Study to Assess the Saf...</td>\n",
       "      <td>Apoptosis stimulants, ERBB 2 receptor antagoni...</td>\n",
       "      <td>Antineoplastics, Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>Immunoconjugates, Immunotoxins, Monoclonal ant...</td>\n",
       "      <td>Advanced breast cancer, Male breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>multicentre, open, prospective</td>\n",
       "      <td>Incidence and severity of adverse events\\nsafe...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Jul 2019 (planned)</td>\n",
       "      <td>Active, no longer recruiting</td>\n",
       "      <td>2019-02-01|Other trial event|Last checked agai...</td>\n",
       "      <td>Advanced breast cancer|treatment|stage IV; Mal...</td>\n",
       "      <td>HER2</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>489</th>\n",
       "      <td>700301177</td>\n",
       "      <td>An Open-label, Non-randomized, Single-dose, Pa...</td>\n",
       "      <td>ERBB 2 receptor antagonists</td>\n",
       "      <td>Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer, Colorectal cancer</td>\n",
       "      <td>Seattle Genetics, Seattle Genetics</td>\n",
       "      <td>multicentre, open, parallel, prospective</td>\n",
       "      <td>Maximum observed concentration\\ndescription: P...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 May 2019 (planned)</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>2019-02-01|Other trial event|Last checked agai...</td>\n",
       "      <td>Breast cancer|treatment|; Colorectal cancer|tr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>570</th>\n",
       "      <td>700301239</td>\n",
       "      <td>A Phase 1, Open-Label, Fixed-sequence, 5-part,...</td>\n",
       "      <td>14-alpha demethylase inhibitors, Angiogenesis ...</td>\n",
       "      <td>Antineoplastics, Antihyperlipidaemics, Antifun...</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer, Colorectal cancer</td>\n",
       "      <td>Seattle Genetics, Seattle Genetics</td>\n",
       "      <td>multicentre, open, parallel, prospective</td>\n",
       "      <td>Area under the concentration-time curve (AUC) ...</td>\n",
       "      <td>...</td>\n",
       "      <td>28 Dec 2018 (actual)</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2019-01-22|Other trial event|Last checked agai...</td>\n",
       "      <td>Breast cancer|treatment|; Colorectal cancer|tr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>915</th>\n",
       "      <td>700302217</td>\n",
       "      <td>A Phase 1, Open-label Study of the Absorption,...</td>\n",
       "      <td>ERBB 2 receptor antagonists</td>\n",
       "      <td>Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer, Colorectal cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>open, prospective</td>\n",
       "      <td>Area under the concentration-time curve (AUC) ...</td>\n",
       "      <td>...</td>\n",
       "      <td>30 Jan 2018 (actual)</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2018-12-05|New trial record|New trial record</td>\n",
       "      <td>Breast cancer|treatment|; Colorectal cancer|tr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1507</th>\n",
       "      <td>700026682</td>\n",
       "      <td>A Study of ARRY-380 in Patients With Advanced ...</td>\n",
       "      <td>ERBB 2 receptor antagonists</td>\n",
       "      <td>Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Advanced breast cancer, Bladder cancer, Colore...</td>\n",
       "      <td>Array BioPharma, Array BioPharma</td>\n",
       "      <td>multicentre, open, prospective</td>\n",
       "      <td>Characterize the safety profile of the study d...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Mar 2013 (actual)</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2018-08-31|Biomarker Update|Biomarkers informa...</td>\n",
       "      <td>Advanced breast cancer|treatment|second-line o...</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1760</th>\n",
       "      <td>700292929</td>\n",
       "      <td>Expanded Access Use of Tucatinib for HER2+ Met...</td>\n",
       "      <td>ERBB 2 receptor antagonists</td>\n",
       "      <td>Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics</td>\n",
       "      <td>prospective</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>(planned)</td>\n",
       "      <td>Suspended</td>\n",
       "      <td>2018-04-05|Other trial event|Last checked agai...</td>\n",
       "      <td>Breast cancer|treatment|second-line or greater...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1812</th>\n",
       "      <td>700264999</td>\n",
       "      <td>Phase 3 study of tucatinib (ONT-380) in combin...</td>\n",
       "      <td>Apoptosis stimulants, ERBB 2 receptor antagoni...</td>\n",
       "      <td>Antineoplastics, Antineoplastics</td>\n",
       "      <td>Drug conjugates, Macrolides, Maytansinoids, 2 ...</td>\n",
       "      <td>Immunoconjugates, Immunotoxins, Monoclonal ant...</td>\n",
       "      <td>Breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>prospective</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>(planned)</td>\n",
       "      <td>Planning</td>\n",
       "      <td>2018-03-09|Other trial event|According to a Se...</td>\n",
       "      <td>Breast cancer|treatment|stage IV</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1814</th>\n",
       "      <td>700265020</td>\n",
       "      <td>A phase 2 study of tucatinib (ONT-380) in comb...</td>\n",
       "      <td>Apoptosis stimulants, ERBB 2 receptor antagoni...</td>\n",
       "      <td>Antineoplastics, Antineoplastics</td>\n",
       "      <td>Drug conjugates, Macrolides, Maytansinoids, 2 ...</td>\n",
       "      <td>Immunoconjugates, Immunotoxins, Monoclonal ant...</td>\n",
       "      <td>Breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Seattle Genetics</td>\n",
       "      <td>prospective</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>(planned)</td>\n",
       "      <td>Planning</td>\n",
       "      <td>2018-03-09|Other trial event|According to a Se...</td>\n",
       "      <td>Breast cancer|treatment|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3880</th>\n",
       "      <td>700235510</td>\n",
       "      <td>Proof-of-concept trial of ARRY-380 in patients...</td>\n",
       "      <td>ERBB 2 receptor antagonists</td>\n",
       "      <td>Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Advanced breast cancer, Brain metastases</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics</td>\n",
       "      <td>prospective</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>(planned)</td>\n",
       "      <td>Planning</td>\n",
       "      <td>2013-08-09|New trial record|New trial record</td>\n",
       "      <td>Advanced breast cancer|treatment|; Brain metas...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>13 rows  41 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       Trial ID                                        Trial Title  \\\n",
       "1     700240183  A Phase 1b, Open-label Study to Assess the Saf...   \n",
       "10    700257487  Phase 2 Randomized, Double-Blinded, Controlled...   \n",
       "16    700304216  A Phase 1, Open-Label, Fixed-Sequence, Drug-Dr...   \n",
       "478   700302859  A Phase 1, Randomized, Partially Double-Blind,...   \n",
       "481   700238859  A Phase 1b, Open-label Study to Assess the Saf...   \n",
       "489   700301177  An Open-label, Non-randomized, Single-dose, Pa...   \n",
       "570   700301239  A Phase 1, Open-Label, Fixed-sequence, 5-part,...   \n",
       "915   700302217  A Phase 1, Open-label Study of the Absorption,...   \n",
       "1507  700026682  A Study of ARRY-380 in Patients With Advanced ...   \n",
       "1760  700292929  Expanded Access Use of Tucatinib for HER2+ Met...   \n",
       "1812  700264999  Phase 3 study of tucatinib (ONT-380) in combin...   \n",
       "1814  700265020  A phase 2 study of tucatinib (ONT-380) in comb...   \n",
       "3880  700235510  Proof-of-concept trial of ARRY-380 in patients...   \n",
       "\n",
       "                                    Mechanism of action  \\\n",
       "1     Antibody-dependent cell cytotoxicity, Antimeta...   \n",
       "10    Antibody-dependent cell cytotoxicity, Antibody...   \n",
       "16    AMP activated protein kinase stimulants, Emiss...   \n",
       "478   DNA gyrase inhibitors, ERBB 2 receptor antagon...   \n",
       "481   Apoptosis stimulants, ERBB 2 receptor antagoni...   \n",
       "489                         ERBB 2 receptor antagonists   \n",
       "570   14-alpha demethylase inhibitors, Angiogenesis ...   \n",
       "915                         ERBB 2 receptor antagonists   \n",
       "1507                        ERBB 2 receptor antagonists   \n",
       "1760                        ERBB 2 receptor antagonists   \n",
       "1812  Apoptosis stimulants, ERBB 2 receptor antagoni...   \n",
       "1814  Apoptosis stimulants, ERBB 2 receptor antagoni...   \n",
       "3880                        ERBB 2 receptor antagonists   \n",
       "\n",
       "                        Drug class (therapeutic effect)  \\\n",
       "1     Antineoplastics, Antineoplastics, Antineoplastics   \n",
       "10    Antineoplastics, Antineoplastics, Antineoplast...   \n",
       "16                 Antineoplastics, Antihyperglycaemics   \n",
       "478                     Antineoplastics, Antibacterials   \n",
       "481                    Antineoplastics, Antineoplastics   \n",
       "489                                     Antineoplastics   \n",
       "570   Antineoplastics, Antihyperlipidaemics, Antifun...   \n",
       "915                                     Antineoplastics   \n",
       "1507                                    Antineoplastics   \n",
       "1760                                    Antineoplastics   \n",
       "1812                   Antineoplastics, Antineoplastics   \n",
       "1814                   Antineoplastics, Antineoplastics   \n",
       "3880                                    Antineoplastics   \n",
       "\n",
       "                                  Drug class (chemical)  \\\n",
       "1     2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "10    2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "16    2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "478   2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "481   2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "489   2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "570   2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "915   2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "1507  2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "1760  2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "1812  Drug conjugates, Macrolides, Maytansinoids, 2 ...   \n",
       "1814  Drug conjugates, Macrolides, Maytansinoids, 2 ...   \n",
       "3880  2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "\n",
       "                                Drug class (biological)  \\\n",
       "1                                 Monoclonal antibodies   \n",
       "10         Monoclonal antibodies, Monoclonal antibodies   \n",
       "16                                                  NaN   \n",
       "478                                                 NaN   \n",
       "481   Immunoconjugates, Immunotoxins, Monoclonal ant...   \n",
       "489                                                 NaN   \n",
       "570                                                 NaN   \n",
       "915                                                 NaN   \n",
       "1507                                                NaN   \n",
       "1760                                                NaN   \n",
       "1812  Immunoconjugates, Immunotoxins, Monoclonal ant...   \n",
       "1814  Immunoconjugates, Immunotoxins, Monoclonal ant...   \n",
       "3880                                                NaN   \n",
       "\n",
       "                                             Indication  \\\n",
       "1            Advanced breast cancer, Male breast cancer   \n",
       "10    Advanced breast cancer, Carcinoma, Male breast...   \n",
       "16                     Breast cancer, Colorectal cancer   \n",
       "478                    Breast cancer, Colorectal cancer   \n",
       "481          Advanced breast cancer, Male breast cancer   \n",
       "489                    Breast cancer, Colorectal cancer   \n",
       "570                    Breast cancer, Colorectal cancer   \n",
       "915                    Breast cancer, Colorectal cancer   \n",
       "1507  Advanced breast cancer, Bladder cancer, Colore...   \n",
       "1760                                      Breast cancer   \n",
       "1812                                      Breast cancer   \n",
       "1814                                      Breast cancer   \n",
       "3880           Advanced breast cancer, Brain metastases   \n",
       "\n",
       "                                          Organisations  \\\n",
       "1     Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "10    Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "16                   Seattle Genetics, Seattle Genetics   \n",
       "478                  Seattle Genetics, Seattle Genetics   \n",
       "481   Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "489                  Seattle Genetics, Seattle Genetics   \n",
       "570                  Seattle Genetics, Seattle Genetics   \n",
       "915   Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "1507                   Array BioPharma, Array BioPharma   \n",
       "1760     Cascadian Therapeutics, Cascadian Therapeutics   \n",
       "1812  Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "1814           Cascadian Therapeutics, Seattle Genetics   \n",
       "3880     Cascadian Therapeutics, Cascadian Therapeutics   \n",
       "\n",
       "                                           Trial Design  \\\n",
       "1              multicentre, open, parallel, prospective   \n",
       "10    double-blind, multicentre, parallel, prospecti...   \n",
       "16                                    open, prospective   \n",
       "478    crossover, double-blind, prospective, randomised   \n",
       "481                      multicentre, open, prospective   \n",
       "489            multicentre, open, parallel, prospective   \n",
       "570            multicentre, open, parallel, prospective   \n",
       "915                                   open, prospective   \n",
       "1507                     multicentre, open, prospective   \n",
       "1760                                        prospective   \n",
       "1812                                        prospective   \n",
       "1814                                        prospective   \n",
       "3880                                        prospective   \n",
       "\n",
       "                                        Trial Endpoints      ...       \\\n",
       "1     Incidence of adverse events\\ntime_frame: Up to...      ...        \n",
       "10    Progression-free survival (PFS) per RECIST 1.1...      ...        \n",
       "16    Maximum observed plasma concentration (Cmax) o...      ...        \n",
       "478   Placebo-corrected change-from-baseline in QTcF...      ...        \n",
       "481   Incidence and severity of adverse events\\nsafe...      ...        \n",
       "489   Maximum observed concentration\\ndescription: P...      ...        \n",
       "570   Area under the concentration-time curve (AUC) ...      ...        \n",
       "915   Area under the concentration-time curve (AUC) ...      ...        \n",
       "1507  Characterize the safety profile of the study d...      ...        \n",
       "1760                                                NaN      ...        \n",
       "1812                                                NaN      ...        \n",
       "1814                                                NaN      ...        \n",
       "3880                                                NaN      ...        \n",
       "\n",
       "             Trial End date                  Trial Status  \\\n",
       "1     01 Jul 2019 (planned)  Active, no longer recruiting   \n",
       "10    01 Jul 2021 (planned)                    Recruiting   \n",
       "16    01 Mar 2019 (planned)                    Recruiting   \n",
       "478   01 Mar 2019 (planned)                    Recruiting   \n",
       "481   01 Jul 2019 (planned)  Active, no longer recruiting   \n",
       "489   01 May 2019 (planned)                    Recruiting   \n",
       "570    28 Dec 2018 (actual)                     Completed   \n",
       "915    30 Jan 2018 (actual)                     Completed   \n",
       "1507   01 Mar 2013 (actual)                     Completed   \n",
       "1760              (planned)                     Suspended   \n",
       "1812              (planned)                      Planning   \n",
       "1814              (planned)                      Planning   \n",
       "3880              (planned)                      Planning   \n",
       "\n",
       "                                          Trial History  \\\n",
       "1     2019-03-06|Other trial event|Last checked agai...   \n",
       "10    2019-03-06|Other trial event|Last checked agai...   \n",
       "16    2019-03-06|Other trial event|Last checked agai...   \n",
       "478   2019-02-03|Other trial event|Last checked agai...   \n",
       "481   2019-02-01|Other trial event|Last checked agai...   \n",
       "489   2019-02-01|Other trial event|Last checked agai...   \n",
       "570   2019-01-22|Other trial event|Last checked agai...   \n",
       "915        2018-12-05|New trial record|New trial record   \n",
       "1507  2018-08-31|Biomarker Update|Biomarkers informa...   \n",
       "1760  2018-04-05|Other trial event|Last checked agai...   \n",
       "1812  2018-03-09|Other trial event|According to a Se...   \n",
       "1814  2018-03-09|Other trial event|According to a Se...   \n",
       "3880       2013-08-09|New trial record|New trial record   \n",
       "\n",
       "                                       Diseases treated Biomarkers-Inclusion  \\\n",
       "1     Advanced breast cancer|treatment|second-line o...                 HER2   \n",
       "10    Advanced breast cancer|treatment|second-line o...                 HER2   \n",
       "16    Breast cancer|treatment|; Colorectal cancer|tr...                  NaN   \n",
       "478   Breast cancer|treatment|; Colorectal cancer|tr...                  NaN   \n",
       "481   Advanced breast cancer|treatment|stage IV; Mal...                 HER2   \n",
       "489   Breast cancer|treatment|; Colorectal cancer|tr...                  NaN   \n",
       "570   Breast cancer|treatment|; Colorectal cancer|tr...                  NaN   \n",
       "915   Breast cancer|treatment|; Colorectal cancer|tr...                  NaN   \n",
       "1507  Advanced breast cancer|treatment|second-line o...                 HER2   \n",
       "1760  Breast cancer|treatment|second-line or greater...                  NaN   \n",
       "1812                   Breast cancer|treatment|stage IV                  NaN   \n",
       "1814                           Breast cancer|treatment|                  NaN   \n",
       "3880  Advanced breast cancer|treatment|; Brain metas...                  NaN   \n",
       "\n",
       "     Biomarkers-Exclusion  Biomarkers-Outcome Measure Biomarkers-Safety  \\\n",
       "1                    HER2                         NaN               NaN   \n",
       "10                   HER2                         NaN               NaN   \n",
       "16                    NaN                         NaN               NaN   \n",
       "478                   NaN                         NaN               NaN   \n",
       "481                  HER2                         NaN               NaN   \n",
       "489                   NaN                         NaN               NaN   \n",
       "570                   NaN                         NaN               NaN   \n",
       "915                   NaN                         NaN               NaN   \n",
       "1507                  NaN                        HER2               NaN   \n",
       "1760                  NaN                         NaN               NaN   \n",
       "1812                  NaN                         NaN               NaN   \n",
       "1814                  NaN                         NaN               NaN   \n",
       "3880                  NaN                         NaN               NaN   \n",
       "\n",
       "      Biomarkers-not specified Primary Drugs  \n",
       "1                          NaN     Tucatinib  \n",
       "10                         NaN     Tucatinib  \n",
       "16                         NaN     Tucatinib  \n",
       "478                        NaN     Tucatinib  \n",
       "481                        NaN     Tucatinib  \n",
       "489                        NaN     Tucatinib  \n",
       "570                        NaN     Tucatinib  \n",
       "915                        NaN     Tucatinib  \n",
       "1507                       NaN     Tucatinib  \n",
       "1760                       NaN     Tucatinib  \n",
       "1812                       NaN     Tucatinib  \n",
       "1814                       NaN     Tucatinib  \n",
       "3880                       NaN     Tucatinib  \n",
       "\n",
       "[13 rows x 41 columns]"
      ]
     },
     "execution_count": 78,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Phase I "
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
